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 Dose verification is a critical component of adaptive radiotherapy, as it provides a 
measurement of treatment delivery success.  Based on the measured outcome, the 
plan may be adapted to account for differences between the planned dose and the 
delivered dose.  Although placement of an EPID behind the patient during treatment 
allows for exit dosimetry which may be used to reconstruct the delivered patient dose 
via backprojection of the fluence, there have not been any studies examining the basic 
assumption of backprojection-based dose verification: that deviations between the 
expected and delivered exit fluences are totally caused by errors in the delivered 
fluence, and not caused by patient geometry changes.  In this dissertation, the validity 
of this assumption is tested.  Exit fluence deviations caused by machine fluence delivery 
errors are measured as well as those caused by interfractional changes in the patient 
anatomy.  Dose reconstruction errors resulting from the backprojection assumption are 
assessed.  Correlations are examined between exit fluence deviations and patient dose 
reconstruction deviations.  Based on these correlations, a decision tree is proposed 
xxviii 
detailing when caution should be taken in performing dose reconstruction to achieve 
delivery verification.  Finally, a semi-automated dose verification tool is constructed for 
both clinical and research purposes.
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1. Introduction 
When diagnosed with cancer, several treatment options are available to the patient 
including surgery, chemotherapy, and radiation therapy.  One type of radiotherapy, 
external beam radiotherapy (EBRT), involves the use of a linear accelerator to produce 
high energy radiation incident on the patient.  A standard workflow for EBRT involves 
imaging the patient with a computed tomography (CT) imager.  The physician then 
identifies the tumor and surrounding normal structures on the CT image and designs a 
plan that will deliver a tumorcidal dose while minimizing damage to normal structures.  
This external beam is delivered at several incident angles on the patient to focus dose 
on the tumor.  Also, to take advantage of the differing recovery rates of cancerous and 
normal tissues, the dose is divided into multiple fractions that are delivered on different 
days across the span of several weeks. 
Simply designing an ideal treatment plan, however, is not sufficient; successful 
delivery of the plan to the patient is equally critical.  Therefore quality assurance (QA) 
tests are performed on the plan on the linear accelerator without the patient present.  
Treatment plan QA ensures both that the plan data is successfully transferred from the 
planning computer to the treatment machine and that the delivered beams are within 
acceptable tolerance of the planned beams. 
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Reproducibility of dose delivery over the course of treatment, however, is 
problematic due to interfractional variation in both patient geometry and the treatment 
machine output.  The treatment plan is optimized on a CT which is acquired several 
days prior to treatment delivery.  Not only is there inherent variation in the patient set-up 
position for each fraction of delivery, but the internal geometry of the patient is also 
constantly changing both inter- and intra-fractionally.  These variations cause the 
delivered patient dose to deviate from the planned dose.  Furthermore, standard plan 
designing assumes no variation in machine output, which is not the case; the beam 
output and positioning involves inherent levels of uncertainty. 
Patient positioning uncertainties can be reduced through image guided 
radiotherapy (IGRT), in which imaging of the patient in the treatment position is used to 
improve daily patient alignment.  Based on time-of-treatment image acquisition, the 
patient may be shifted in order to reduce deviations between the planned position and 
treatment position.  The radiotherapy is ―guided‖ by the imaging. 
Treatment delivery may also be improved through a process termed image-
guided adaptive radiotherapy (IGART), in which the treatment plan is adapted to 
geometric patient changes throughout treatment delivery.  IGART allows for adaptation 
to a changing treatment geometry with the goal of achieving a dose distribution 
(accumulated over the fractional deliveries) that more closely achieves the planned 
outcome, compared to delivery of the initial planned treatment for every fraction.  For 
example, if the tumor shrinks as each fraction is delivered, the treatment may be 
adapted by shrinking the incident beam sizes, thereby sparing dose to the surrounding 
normal tissue. 
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IGART necessitates feedback between the patient status during delivery and 
during planning.  IGART also has the potential to correct for deviations between 
delivered and planned dose, but in order to do so, the delivered dose must be 
measured.  When this measurement is fed back to the planning system, radiation 
therapy planning and delivery becomes a closed loop system.  A judgment may be 
made on how well the treatment was delivered, and whether or not the treatment should 
be replanned to account for delivered dose deviations.  Direct measurement of the 
received patient dose (in vivo dosimetry) is not feasible; it would require dosimeters to 
be implanted throughout the patient.  Therefore, an indirect method of dose verification 
is more realistic.  This indirect measurement may be achieved with a dosimeter 
measuring the patient exit fluence (the radiation that transmits through patient), which 
includes primary incident radiation and the attenuation of the beam by the patient.  
Based on deviations between expected and measured exit fluences, accuracy of the 
delivered patient dose may be inferred. 
Patient exit fluence measurements have been used in direct comparison with 
expected fluence predictions for visual verification of treatment delivery (Talamonti, 
Casati et al. 2006; van Zijtveld, Dirkx et al. 2006; Bailey, Kumaraswamy et al. 2012).  
While the exit fluence comparison allows for treatment validation, it only provides limited 
guidance when deviations are observed.  Exit fluence measurements have also been 
used to estimate the delivered patient dose via a technique called patient dose 
reconstruction (Louwe, Damen et al. 2003; Steciw, Warkentin et al. 2005; Wendling, 
Louwe et al. 2006; Louwe, Wendling et al. 2007; McDermott, Wendling et al. 2008; 
Wendling, McDermott et al. 2009; Mans, Wendling et al. 2010).  On the surface, this 
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seems to provide direct verification of the dose received.  It does so by backprojecting 
the measured exit fluence through a presumed patient anatomy and estimating dose.  
However, the exit fluence is a result of the incident fluence and the patient attenuation.  
Backprojection implicitly assumes that the patient anatomy is unchanged and therefore, 
measured exit fluence deviations are only due to deviations in the fluence incident on 
the patient.  Commercial products are being developed based on this backprojection 
assumption of idealized anatomy. 
This dissertation examines exit dosimetry by (a) directly isolating and quantifying 
sources of exit fluence deviations and (b) assessing the dosimetric consequences of 
attributing patient-caused exit fluence deviations to incident fluence deviations.  
Repeated EPID measurements of test fields were used to evaluate the precision of 
beam delivery.  Exit fluence deviations resulting from patient changes were quantified 
via computer simulation methods to ensure exact knowledge of the simulated patient 
anatomies and machine output.  Together, these quantifications assess the 
assumptions of ―backprojection‖ exit fluence-based dose reconstruction.  To assist in 
this analysis, a semi-automated dose verification and comparison tool was created.  
This tool is useful not only for this dissertation, but also for efficiency gains in clinical QA. 
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2. Background and Significance 
2.1. Image Guided Adaptive Radiotherapy 
Image guided adaptive radiotherapy (IGART) combines image guidance with adaptive 
radiotherapy (ART).  Image guidance not only improves patient positioning throughout 
the treatment, but also has the potential to update the patient geometry.  The updated 
geometry may then be used for adaptive treatment planning or treatment re-optimization 
in order to account for differences between the original planning geometry and the 
updated geometry. 
One of the first implementations of ART was proposed by Yan et al. (Yan, Vicini 
et al. 1997) to account for patient-specific anatomy variability.  During the first week of 
treatment, a fan-beam CT (FBCT) of the patient was acquired each day.  Based on the 
measured distribution of patient geometries, a patient-specific margin was incorporated 
into the replanned treatment, which was delivered starting in the second week of 
treatment.  Letourneau et al. (Letourneau, Wong et al. 2007) proposed an online IGART 
system in which, for each treatment fraction, a cone beam CT (CBCT) of the patient 
was acquired, critical volumes were defined, and treatment was replanned  while the 
patient was on the treatment couch.  In this scenario, the only opportunity for delivery 
QA is during treatment delivery. 
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Another instance of IGART was developed at the University of California San 
Francisco: dose-guided radiation therapy (DGRT) (Cheung, Aubry et al. 2009).  This 
scheme involves adaptation of the treatment plan by accounting for daily differences 
between the dose-of-the-day and the planned dose.  In their proposed method, while 
the patient is on the treatment couch immediately prior to delivery, a megavoltage CT 
(MVCT) of the patient is acquired.  This MVCT is corrected for various artifacts 
associated with MV imaging.  Since the field of view of an MVCT is not as large as an 
FBCT, any critical missing data from the MVCT reconstructed geometry is assumed 
using knowledge of the patient geometry from the FBCT acquisition.  Critical structures 
are recontoured, and replanning takes place while the patient remains on the treatment 
couch.  Differences between the original planned dose distribution and the new, 
adapted dose distribution can be visualized in the control room, and the adapted plan is 
delivered to the patient.  This system was tested on six head-and-neck (H/N) patients as 
well as two prostate patients.  While the DGRT-adapted plan didn‘t show improvement 
in target coverage, there was improvement in sparing of the organs at risk surrounding 
the target. 
When IGART is implemented, treatment replanning may result in a change to the 
delivered fluence.  However, quality assurance (QA) of the delivered fluence is needed.  
One method is exit fluence measurement and comparison with planned exit fluence.  
This exit fluence comparison method is used in this work, while other methods are also 
examined. 
 7 
2.2. Dose Verification Using Portal Dosimetry 
The device used to measure the exit fluence must be accurate and reproducible.  An 
electronic portal imaging device (EPID) provides both high resolution (0.4 mm x 0.4 mm) 
and accurate, precise measurements.  The dose-response of three commercially 
available EPIDs (Siemens, Elekta, Varian) has been characterized (McDermott, Louwe 
et al. 2004; Nijsten, van Elmpt et al. 2007).  In this dissertation, Varian aS500 and 
aS1000 EPIDs were used.  Greer et al. (Greer and Popescu 2003) and Van Esch et al. 
(Van Esch, Depuydt et al. 2004), found that dose response and dose-rate response 
were approximately linear for a Varian aS500 EPID.  Greer et al. also found that there 
was a field-size response of -2% for a 4×4 cm2 field relative to a 10×10 cm2 field and a 
+2.5% response for a 24×24 cm2 field relative to a 10×10 cm2 field with respect to 
ionization chamber measurements in water.  This field size response was caused by 
backscattering from the EPID positional arm and has been reproduced though 
simulations at our institution.  Dosimetric differences due to field-size response are 
accounted for through backscattering correction factors (Wang, Gardner et al. 2009).  
Greer et al. also concluded that the buildup effect was insignificant for 6 MV beams. 
2.2.1. Pretreatment Verification 
For intensity modulated radiotherapy (IMRT), pretreatment delivery of the patient 
radiation fields to a dosimeter is performed in order to validate transfer of the treatment 
planning information from the treatment planning system (TPS) to the linac, as well as 
the deliverability of the treatment (Ezzell, Burmeister et al. 2009).  The accelerator 
output fluence corresponding to each treatment field is measured without the patient in 
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the field prior to treatment delivery.  This fluence can be compared to the expected 
fluence (Talamonti, Casati et al. 2006; van Zijtveld, Dirkx et al. 2006; Bailey, 
Kumaraswamy et al. 2012) or used to estimate the patient dose distribution 
corresponding to the delivered fluence in order to verify delivered and planned dose 
distributions (van Elmpt, Nijsten et al. 2006; van Zijtveld, Dirkx et al. 2007; van Elmpt, 
Nijsten et al. 2008). 
The basic goal of pretreatment delivery is to ensure accurate patient treatment 
dose delivery.  The task group (TG) report on IMRT commissioning (Ezzell, Burmeister 
et al. 2009) recommends that delivered dose be within 5% of planned dose in areas of 
high dose and low gradient, and within 7% in areas of low dose and low gradient.  Also, 
90% of delivered dose points should agree within 3% and 3 mm with the expected dose 
points.  Pretreatment verification can detect delivery errors caused by transfer failure of 
the treatment plan between the planning system and the delivery system.  This failure 
might result from human errors (e.g. selecting the wrong plan to transfer to the delivery 
machine) or from system errors (e.g. network transmission).  Pretreatment verification 
can also catch errors caused by linac‘s inability to accurately deliver the planned 
treatment.  This failure potentially could be caused by variation in the accelerator output 
or the physical limitations of the multileaf collimator (MLC).  Either of these deviations 
could be detected through use of pretreatment verification. 
One shortcoming of pretreatment verification, however, is that the during-
treatment delivered dose is not verified.  There is a critical assumption being made that 
the treatment machine will reproduce the pretreatment fluence for each treatment.  
Changes or errors introduced between pretreatment verification and treatment delivery 
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will escape detection.  Therefore during-treatment verification is necessary to validate 
daily dose delivery. 
2.2.1.1. Gamma Comparison Metric 
Whether comparing two two-dimensional images, such as fluence maps, or two three-
dimensional images, such as patient dose maps, the standard comparison metric for 
verification is the gamma metric (Low and Dempsey 2003).  The gamma metric 
combines both the dose difference between the same pixel in an evaluated and a 
reference image as well as the distance-to-agreement (DTA) between the evaluated 
image pixel and the closest pixel in the reference image that equals that value.  The 
user sets tolerances levels for both metrics—for example, a 3% dose difference 
tolerance and a 3 mm DTA tolerance.  The gamma value for each pixel is calculated 
using the following formula: 
 
where  is the spatial distance between the evaluated and reference dose points, 
 is the difference between the evaluated dose  at position  and reference 
dose  at position ,  is the DTA tolerance, and  is the dose difference 
tolerance.  A pixel which fails either the DTA or dose difference tolerances will have a 
gamma value greater than one.  The per-pixel gamma results can be plotted so that 
areas of failure are evident.  TG Report 119 recommends that 90% of pixels pass the 
gamma metric with tolerances of 3% and 3 mm (Ezzell, Burmeister et al. 2009). 
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 Naïve usage of the gamma metric, however, can lead to misleading results.  MC-
generated images have abnormally high gamma pass rates since the inherent statistical 
noise in the simulation yields lower DTAs between the evaluated and reference images.  
Also, even though the gamma metric is generally accepted as the proper comparison 
metric, there is poor correlation between gamma passing rates and delivery success 
(Yan, Liu et al. 2009; Nelms, Zhen et al. 2011; Gordon, Gardner et al. 2012). 
2.2.1.2. DPI Comparison 
Pretreatment dosimetric portal image (DPI) validation entails comparison of measured 
DPIs for each treatment beam with DPIs predicted based upon beam information in the 
TPS.  These expected DPIs can be directly predicted by some TPSs (such as Varian‘s 
PortalVision software based on Van Esch et. al.) (Van Esch, Depuydt et al. 2004), 
computed with external analytic programs (Van Esch, Vanstraelen et al. 2001), or 
computed via Monte Carlo (MC) radiation transport simulations (Siebers, Kim et al. 
2004; Parent, Seco et al. 2006).  Differences between the actual and predicted fluences 
ideally can be pinpointed to machine-related variations or treatment plan data transfer 
failure.  Subsequently, these errors can be corrected prior to actual patient treatment. 
EPID-based pretreatment fluence verification has been performed at several 
institutions (Talamonti, Casati et al. 2006; van Zijtveld, Dirkx et al. 2006).  At the 
University of Florence hospital, an aSi EPID was dosimetrically calibrated to match 
TPS-generated doses over a range of field sizes for beam energy 6 MV.  Comparisons 
between measured and simulated fields for a series of fifteen clinical IMRT fields 
resulted in an average of 97.6% of pixels passing gamma for criteria of 3% and 3 mm.  
This agreement was comparable to that achieved when radiographic film was used to 
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measure the delivered fluence.  The EPID was preferred over film for pretreatment 
verification, due to the greater time and effort required to use film (Talamonti, Casati et 
al. 2006).  Pretreatment verification using DPI comparison had been performed at the 
Erasmus Cancer Center in Rotterdam for three years by 2006.  In 270 patient treatment 
courses, four clinically relevant errors were caught.  One instance involved the wrong 
plan transmitted to the treatment machine, while the other three involved MLC leaf 
malfunctions (van Zijtveld, Dirkx et al. 2006). 
As arc therapy has become more widespread over the past several years, EPID-
based pretreatment verification has been utilized in that modality as well.  At the 
Roswell Park Cancer Institute in Buffalo, two EPID dosimetry systems were compared 
to a standard diode array for fourteen prostate arcs and twelve head and neck (H/N) 
arcs.  On average, both systems yielded 98% of pixels passing gamma (3%, 3 mm) for 
the prostate cases, and 95% for the H/N cases (Bailey, Kumaraswamy et al. 2012). 
One of the goals of this work is to provide our institution the framework for using 
DPI-based pretreatment verification.  Prior to 2009, in addition to independent MC 
calculations, our clinic performed IMRT QA through visual inspection of differences 
between the planned and measured DPIs.  Afterwards, this qualitative method was 
replaced by a quantitative one: using an I‘mRT Matrixx (IBA Dosimetry America, 
Bartlett, TN) two-dimensional array of ionization chambers, and its accompanying 
comparison software.  This comparison outputs the frequency of pixels that pass 
gamma (i.e. have gamma values less than one) with tolerance levels set to those 
recommended in TG 119 (Ezzell, Burmeister et al. 2009).  Since there are inherent 
advantages to an EPID-based verification system, the goal is to revert back to that 
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system, but with added improvements in automation and quantitative assessment 
(discussed in section 5.1), notably improving upon the potentially misleading gamma 
metric. 
2.2.1.3. Patient Dose Reconstruction 
As the true goal of QA processes is to ensure that treatment delivery will result in the 
planned treatment dose, an enhancement of pretreatment verification is to use the 
measured DPIs to reconstruct the delivered dose in a planning CT geometry.  In this 
case, instead of determining the success of the delivery based on deviations in the 2-D 
DPI, a judgment may be made based on deviations between the original planned and 
reconstructed 3-D patient dose.  In a pretreatment context, EPID-based patient dose 
reconstruction is achieved by backprojecting fluence (as measured by DPIs at the EPID 
measurement plane) to the exit of the accelerator head, and then utilizing this fluence in 
a forward calculation of the patient dose (van Elmpt, Nijsten et al. 2006; van Zijtveld, 
Dirkx et al. 2007).  Some current commercial pretreatment QA products (MapCHECK, 
Sun Nuclear) use this method of verification. 
 At the University Hospital Maastricht, pretreatment patient dose reconstruction 
was performed on nine 3D conformal lung plans and five IMRT H/N plans (van Elmpt et 
al. 2008).  Differences between the planned and reconstructed patient dose DVHs were 
used for judgment of delivery success.  Differences less than 5% were observed in the 
mean PTV dose for the lung cases, while there were no significant differences in the 
lung and spinal DVH parameters.  For the H/N cases, differences in the mean PTV dose, 
the mean parotid dose, and the maximum spinal cord dose were about 3%. 
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 In similar work, physicists at Erasmus iteratively estimated the incident fluence 
required to produce the measured exit fluence, then utilized that fluence in a patient 
dose calculation (van Zijtveld et al. 2007).  Their method was demonstrated for ten 
head-and-neck (H/N) cancer treatment plans and five rectum cases.  Gamma analysis 
(2%, 2 mm) showed agreement in more than 95% of voxels.  Differences in DVH 
parameters were less than 2%.  Also, two of the cases which previously failed their 
earlier DPI-comparison method were re-examined using patient dose reconstruction.  In 
the case of the MLC leaf malfunction, it was observed that DVH comparison resulted in 
good agreement for the PTV dose.  However, the gamma analysis showed local failure 
in the PTV volume over which the malfunctioning MLC leaf was positioned.  It was 
concluded that simple DVH analysis of the reconstructed patient dose was not a 
sufficient means to catch significant local errors; however, using a 3-D gamma analysis 
would detect these errors. 
 Pretreatment patient dose reconstruction based on measured delivery fluences is 
useful to detect deviations between dose distributions approved by the physician during 
the treatment planning process.  Similar to pretreatment fluence-based DPI 
comparisons, pretreatment dose reconstruction inherently cannot detect unintended 
alterations in the treatment delivery after pretreatment QA is performed.  Furthermore, 
as treatment planning transitions from a once- or twice-per-treatment process to a daily 
online process, the ability to do pretreatment QA diminishes.  When a treatment plan is 
generated based upon a time-of-treatment image of the patient on the treatment 
machine, it is neither practical nor desirable to move the patient for the purposes of 
performing pretreatment QA. 
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2.2.2. During Treatment Verification 
As noted previously, shortcomings of pretreatment verification include its inability to 
detect intentional changes in the treatment plan or unintentional changes in the delivery, 
either via changes in the record and verify (R&V) database or equipment failures.  
These changes, however, can be detected using during-treatment measurements.  In 
this scenario, the imager is extended behind the patient during treatment delivery, and a 
through-patient image is acquired for each delivered beam.  Instead of comparing the 
planned dose to the expected dose, the planned dose may now be directly compared to 
the predictions of the delivered dose.  Although passive during-treatment QA may not 
prevent delivery of deviant doses, it will detect deviant dose delivery and can enable 
treatment delivery adaptations of future fractions to achieve the planned treatment. 
 Active during-treatment QA, which monitors exit fluence as it is being delivered 
and compares it with expected fluence delivery, has the potential to prevent gross 
treatment delivery errors (Mutanga, de Boer et al. 2012).  Both determining treatment 
adaptations and implementation of a closed-loop active delivery QA system are beyond 
the scope of this work.  This work‘s goal is to detect and classify delivery deviations 
which would trigger plan adaptation. 
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Figure 1: Flow chart for exit fluence-based delivery verification.  For pretreatment verification, the DPI is simulated 
without the patient geometry present in the beam.  For during-treatment verification, the DPI is simulated through an 
assumed patient geometry. 
 
2.2.2.1. DPI Comparison 
The information flow for during-treatment DPI acquisition is shown in Figure 1.  Similar 
to pretreatment verification, during-treatment verification can be accomplished via direct 
comparison of DPIs or by patient dose reconstruction.  Simulating during-treatment 
DPIs requires an estimate of the fluence incident upon the patient as well as an 
estimate of the patient geometry.  The former can be obtained from the TPS or a 
simulation of the beam delivery, while the latter can be obtained from the treatment 
planning CT image or a more recent image of the patient anatomy, e.g. from a 
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pretreatment image of the patient on the treatment machine.  Using this input image, 
simulated DPIs can be generated via analytic or MC methods (Kroonwijk, Pasma et al. 
1998; Pasma, Heijmen et al. 1998; McCurdy and Pistorius 2000; McCurdy, Luchka et al. 
2001).  These simulated DPIs are then compared with the measured DPIs for each field 
to determine if the treatment was delivered successfully. 
Pasma et al.(Pasma, Heijmen et al. 1998) predicted DPIs by ray-tracing the 
primary fluence through the patient CT and then adding a rotationally-symmetric scatter 
kernel to account for scatter.  McCurdy et al. (McCurdy and Pistorius 2000; McCurdy, 
Luchka et al. 2001) predicted DPIs by ray-tracing the incident fluence through the 
patient CT and then adding a MC-calculated scatter portion.  Kroonwijk et al.(Kroonwijk, 
Pasma et al. 1998) were able to detect the presence of air pockets in the rectum in 
prostate cases due to differences between the simulated and measured DPIs.  In all of 
these studies, the expected exit fluence was calculated based on the patient geometry 
obtained from the planning CT. 
In this work, two different methods were used to simulate during-treatment DPIs: 
1) MC simulation and 2) calculation of an attenuation-based primary component 
combined with an estimate of a scatter component.  While the former method should 
provide accurate DPI estimates, it can be CPU intensive (time consuming).  While the 
accuracy of the latter method is less than that of MC simulation, I hypothesize that it will 
still be sufficient to detect gross delivery errors. 
2.2.2.2. Patient Dose Reconstruction 
The measured DPI can also be used to reconstruct the patient dose (Louwe, Damen et 
al. 2003; Steciw, Warkentin et al. 2005; Talamonti, Casati et al. 2006; Wendling, Louwe 
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et al. 2006; McDermott, Wendling et al. 2008; Wendling, McDermott et al. 2009; Mans, 
Wendling et al. 2010).  Patient dose reconstruction is more prevalent than comparison 
of expected and actual DPIs because it allows for dose verification of the three-
dimensional patient dose, whereas comparison of DPIs does not provide such a 
straightforward understanding of delivered dose. 
 
Figure 2:  Flow chart for dose reconstruction-based delivery verification.  To backproject the exit fluence for dose 
reconstruction, the best estimate of the patient geometry is assumed.  The reconstructed dose is then compared to 
the planned dose. 
 
Patient dose reconstruction requires backprojection of the measured fluence 
through the patient geometry.  A flow chart of this process is shown in Figure 2.  A DPI 
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is acquired during treatment delivery.  The exit fluence is obtained from the DPI by 
deconvolving the image with kernels which were calculated to match simulated DPIs 
with measured DPIs.  At this point the exit fluence contains both the primary fluence 
(which transmitted through the patient without interaction) and patient scatter.  
Backprojection of the patient scatter is inappropriate because the source of each scatter 
particle inside the patient is unknown.  Since an estimate of the patient scatter is 
obtainable via MC simulation, this estimate may be subtracted from the exit fluence, 
leaving the primary exit fluence.  The primary fluence is then backprojected to achieve 
dose reconstruction. 
One method to reconstruct the dose involves backprojecting the primary fluence 
through the patient back to its source in the accelerator head.  The fluence is then 
placed incident on the patient and used to calculate the patient dose in a forward 
manner (Talamonti, Casati et al. 2006).  Another method involves backprojecting the 
primary fluence into the patient to reconstruct the primary dose.  The fluence is then 
convolved with an appropriate kernel to estimate the scatter component of the patient 
dose (Wendling, Louwe et al. 2006). 
 One of the leading institutions in backprojection-based patient dose 
reconstruction is the Netherlands Cancer Institute-Antoni van Leeuewnhoek Hospital 
(NKI).  In their system the measured DPI is backprojected to a plane through isocenter 
inside the patient which is normal to the beam direction, while accounting for the 
inverse-square law, beam attenuation, and scatter originating from the patient, the table, 
and the EPID itself.  While single planar dose is not three-dimensional dose 
reconstruction, the planned and reconstructed planar doses in the patient plane typically 
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agree within 1% for IMRT fields (Wendling, Louwe et al. 2006).  Updates to this method 
include use of time-of-treatment cone beam CTs (CBCTs) (McDermott, Wendling et al. 
2008),  expanding dose estimation to 3D (Wendling, McDermott et al. 2009), and arc 
therapy dose reconstruction (Mans, Wendling et al. 2010).  The NKI fluence 
backprojection essentially reconstructs the dose distribution in the accelerator 
coordinate system, thereby permitting comparison of the planned and delivered 
planning target volume (PTV) dose distributions. 
A base assumption of patient dose reconstruction is that the patient geometry is 
equal to that assumed for dose reconstruction.  Any changes to the patient geometry 
between the time of imaging and the time of treatment delivery are ignored.  During 
patient dose delivery, the patient exit fluence is formed from 1) the fluence entering the 
patient, 2) attenuation by the patient, and 3) scattered radiation from the patient.  When 
the exit fluence is backprojected through the patient geometry for dose reconstruction, 
any differences between the expected and measured patient exit fluences are attributed 
completely to deviations in the delivery of the fluence entering the patient independent 
of whether such deviations are plausible or not. 
In this dissertation, I hypothesize that differences between expected and 
measured patient exit fluences are not completely due to deviations in the fluence 
incident on the patient.  Specifically, this work quantifies fluence delivery errors and 
analyzes exit fluence deviations caused by changes in the patient geometry.  
Furthermore, I conjecture that exit fluence deviations are primarily caused by variations 
in patient anatomy, and therefore, caution should be used when relying on patient dose 
reconstruction to achieve delivery verification. 
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2.2.3. EPID-based Verification Tools 
A potentially significant increase in workload for clinicians is required if each measured 
and expected DPI must be compared visually and presence of any significant 
differences determined.  To avoid the extra time required for comparison, some semi-
automatic comparison tools have been implemented which sort out any cases where 
there are clearly no significant differences between the DPIs (van Zijtveld, Dirkx et al. 
2006; Mans, Wendling et al. 2010). 
 Van Zijtveld et al. (van Zijtveld, Dirkx et al. 2006) implemented a pretreatment 
fluence verification system in which visual inspection of the DPIs was avoided in two-
thirds of the cases for 270 patients.  For automatic approval, each field had to pass 
three tests: 
 The percentage of pixels failing gamma (3% / 3 mm) had to be less than 15%. 
 The largest area of gamma failure had to be less than 5 cm2. 
 If failure areas larger than 1 cm2 existed, each area had to have an average 
gamma less than 1.5 and a maximum gamma less than 2. 
If a field failed any of these criteria, then it was flagged for manual review.  Their semi-
automatic comparison tool was able to catch four cases in which the differences were 
clinically significant: in three cases a MLC leaf was malfunctioning, and in the fourth 
case the incorrect patient plan was loaded.  The comparison metric they based their 
decisions on was the gamma index. 
 Both pretreatment and during-treatment verification systems have been in place 
at the NKI since 2005.  From 2005 to 2009, of the 4337 patient treatment plans verified, 
seventeen major plan deviations were detected, including deviations caused by patient 
 21 
anatomy changes (six), transmission failure between the TPS and treatment machine 
(four), suboptimal tuning of the treatment plan (two), accidental modification of the 
record-and-verify system immediately prior to treatment delivery (two), an undeliverable 
plan (one), and the treatment machine skipping a segment of an IMRT delivery (one).  
Together, these systems show the positive potential of EPID-based treatment 
verification. 
In this dissertation, a semi-automatic comparison tool was created for 
pretreatment and during-treatment fluence validation.  In addition to the gamma metric 
employed by others, comparison metrics based on dose differences were used.  While 
the DTA component of the gamma metric is useful for accounting for EPID positioning 
errors, it is also capable of producing false positives and negatives in the presence of 
fluence deviations caused by changes in the patient anatomy.  The developed tool can 
alert the user when differences between the planned and delivered exit fluences are 
significant, thereby ―closing the loop‖ of radiation therapy treatment delivery. 
 
 
2.3. Hypothesis and Goals 
The overriding goal of my dissertation is to develop a clinically viable treatment dose 
validation system utilizing EPID-based fluence verification.  In pursuit of this goal, the 
base assumptions of dose reconstruction were tested.  The sizes of fluence deviations 
caused by the treatment accelerator were experimentally quantified to test the 
plausibility of attributing measured exit fluence deviations to changes in the input 
fluence.  The impacts of changing patient anatomies on exit fluence were quantified by 
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developing a Monte Carlo simulation framework which permitted dose computation on 
multiple patient anatomies both with and without back-projection based fluence 
adjustments. 
In this work it was hypothesized that patient anatomical variations, as opposed to 
variations in the fluence produced by the accelerator, have a greater likelihood to alter 
exit fluences.  It was hypothesized that dose reconstruction can be erroneous if it is 
falsely assumed that all exit fluence deviations are caused by machine-related entrance 
fluence deviations.  Furthermore, it was surmised that comparison of predicted and 
measured exit fluences would be a sufficient means of dose verification, while 
comparison of planned and reconstructed patient doses should only be performed when 
minimal exit fluence deviations exist.  A QA flow chart was formed to determine when 
fluence-based or patient dose-based verification should be implemented.  To permit 
implementation of EPID-based QA, a semi-automatic tool was developed to aid 
treatment delivery verification by comparing the expected and measured exiting 
fluences. 
 Comparison of machine- and patient-related sources of exit fluence deviations is 
covered in section 3 of this work.  Examination of delivery verification errors caused by 
reliance on the backprojection assumption required by patient dose reconstruction is 
made in section 4.  Design and function of the semi-automatic verification tool is 
reported in section 5.  Final discussion and conclusions appear in section 6. 
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3. Sources of Exit Fluence Deviations 
As previously mentioned, during-treatment exit fluence deviations from expected can be 
caused by changes in the incident fluence or changes in the patient attenuation.  While 
dose backprojection inherently assumes the former, the frequency and plausibility of 
this assumption has not been confirmed.  As a goal of this dissertation is to separate 
delivery machine related and patient attenuation related sources of exit fluence 
deviations, this chapter examines these two sources. 
Separate experiments were set up to isolate and estimate the machine-related 
and patient-related sources of exit fluence variability.  Machine-related sources were 
quantified via repeated measurements of fluence delivery without a patient or phantom 
in the beam.  This material is described briefly in Section 3.1 with details published in 
Physics, Medicine, and Biology (Gardner, Clews et al. 2009) as well as presented at the 
Electronic Portal Imaging International Workshop in 2008.  The journal article is shown 
in Appendix I.  Quantification of patient-related sources of exit fluence deviations 
required decoupling of the patient-related sources from machine-related sources.  To 
accomplish this, MC radiation transport simulations were employed.  In the simulation 
environment, the entrance fluence could be exactly replicated and placed incident on a 
series of CT images for a given patient.  Therefore all calculated exit fluence deviations 
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could be attributed to changes in the patient geometry and not to changes in entrance 
fluence or imager fluctuation.  Details of the MC system are given in Section 3.2.1. 
3.1. Fluence Variation Caused by Machine-related Variability 
The goal of this study was to quantify machine-related source of DPI variability.  
Machine-related sources of DPI variability were separated into two broad categories: 1) 
those related to the generation of the incident beam, and 2) those related to 
measurement fluctuations inherent in the detection system.  Incident fluence sources 
include linac output fluctuation as well as positioning variance of the linac head 
components including MLC positions during IMRT delivery.  Measurement sources 
include EPID pixel calibration variations and detector positioning variations. 
Measurements were acquired at beam accelerating potentials of 6 MV and 
18 MV of the following fields: 
 Calibration flood and dark fields 
 Full-imager field 
 10×10 cm2 field 
 Picket fence field, which formed 1 mm-wide regions of high intensity every 3 cm 
 Complex prostate dynamic MLC IMRT field 
Over the span of two months, sixty images were acquired of each field.  The reader is 
encouraged to review Appendix I for the remaining details of the experimental setup.  
Results will be repeated here briefly. 
 25 
 
Figure 3: Dependence of averaged central axis area on averaged size and shape for flood fields.  Circular areas of 
different diameters are shown in the left plot and square areas of different side lengths are shown in the right plot.  
Maximum variation is less than 0.2%. 
 
The calibration variability of the EPID was found to be independent of the size or 
shape of the averaged central axis area from 1 cm2 to 400 cm2 (Figure 3).  The relative 
daily outputs as measured by the average of the central axis area are seen in Figure 4 
and Figure 5.  The standard deviations (SDs) of the central axis area of the calibration 
flood fields, shown in Figure 6 and Figure 7, were 3.0% and 1.9% for the 6MV and 18 
MV accelerating potentials, respectively.  These SDs correspond to the combination of 
accelerator output variation and EPID detection variation.  The SDs in the central axis 
area of the flood field images, which were corrected for daily output variations by daily 
dark/flood field calibration applied, were 0.2% for both accelerating potentials.  
Calibrating measured images to daily-acquired calibration fields effectively eliminates 
fluence variability due to accelerator output variation and EPID response variation. 
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Figure 4: Relative daily output, as measured by the average of the central axis area of flood field images for a 6 MV 
accelerating potential.  The blue circles correspond to the calibration flood fields, while the red circles correspond to 
the flood field images, which were normalized to the calibration flood fields. 
 
 By acquiring repeated measurements of the fields while adjusting the jaws 
between measurements, I found that the uncertainty in the jaws positioning was less 
than 0.2 mm (1 SD) at isocenter for each jaw.  This uncertainty is less than half the size 
of an aS1000 pixel.  The maximum pixel SD caused by the jaws positioning uncertainty 
was 2.3%.  The pixel SD image is shown in Figure 8. 
Repeated measurements while repositioning the EPID between measurements 
showed that the measured uncertainty in the EPID positioning was also less than half of 
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a pixel at isocenter.  The EPID positioning variation caused a maximum fluence pixel 
SD of 1.3%, as seen in Figure 9. 
 
Figure 5: Relative daily output, as measured by the average of the central axis area of flood field images for a 18 MV 
accelerating potential.  The blue circles correspond to the calibration flood fields, while the red circles correspond to 
the flood field images, which were normalized to the calibration flood fields. 
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Figure 6: Standard deviation (SD) maps for the 6 MV calibration flood field (top left) and flood field image (bottom 
left), along with corresponding histograms of the SD values. 
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Figure 7: Standard deviation (SD) maps for the 18 MV calibration flood field (top left) and flood field image (bottom 
left), along with corresponding histograms of the SD values. 
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Figure 8: Fluence variability caused by uncertainty in jaws positioning.  The intensity represents the standard 
deviation (SD) of each pixel over 100 images, between which the jaws were moved to form a 20×20 cm
2
 field and 
then moved back to the original 10×10 cm
2
 field.  The maximum fluence uncertainty (1 SD) at the field edge was 
2.3%.  The x-jaws are located on the right and left edges, while the y-jaws are located on the top and bottom edges. 
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Figure 9: Fluence variability caused by uncertainty in EPID positioning.  The intensity represents the standard 
deviation (SD) of each pixel over 100 images, between which the imager was retracted and re-extended.  The 
maximum fluence uncertainty (1 SD) at the field edge was 1.3%. 
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Figure 10: Patient test field is shown in the top row, while the picket fence MLC test field is shown in the bottom row.  
The first column shows the fields themselves, while the second column shows the pixel standard deviations 
(calculated over 60 images) in the inset with the histogram of the pixel SDs outside.  The inset of the third column 
shows the largest difference between any two images over the 60 images, along with the corresponding histogram of 
the differences on the outside. 
 
Images of a 6 MV picket-fence test field and a patient test field are seen in Figure 
10, along with their corresponding pixel SD images and the largest difference image 
between any two measured fields.  The largest calculated pixel SD for the picket-fence 
fields were 2.1% and 2.3% for the 6 MV and 18 MV accelerating potentials, 
respectively.  The largest calculated pixel SD for the patient fields were 1.0% and 1.1% 
for the 6 MV and 18 MV fields, respectively.  The largest percent difference between 
any two picket-fence fields was 9.8% (6 MV) and 8.4% (18 MV).  The largest percent 
difference between any two patient fields was 4.2% (6 MV) and 3.5% (18 MV). 
In addition to comparing raw images, images were compared after registration 
and normalization.  Inclusion of this preprocessing reduced the pixel SDs of the picket-
fence field to 1.6% (6 MV) and 1.8 % (18 MV), and the patient field to 0.8% (6 MV) and 
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0.9% (18 MV).  These results are summarized in Table 1.  Utilizing registration and 
normalization therefore improves the detectability of exit fluence deviations (Gordon, 
Gardner et al. 2012). 
Table 1: Maximum pixel standard deviations (over 60 images) and percent differences (between any two images) for 
the picket-fence MLC test field and a patient test field for beam accelerating potentials of 6 MV and 18 MV, both with 
and without rigid registration and output normalization. 
 Maximum percent 
difference (%) 
Maximum 
pixel SD (%) 
Maximum pixel SD (%) with 
rigid registration and output 
normalization 
Picket fence 
6 MV 9.8 2.1 1.6 
18 MV 8.4 2.3 1.8 
Patient field 
6 MV 4.2 1.0 0.8 
18 MV 3.5 1.1 0.9 
 
 The purpose of this study was to measure the fluence variation caused by 
machine-related sources, so that the basic assumption of backprojection-based dose 
reconstruction could be tested: that patient-related sources of fluence variation are 
negligible compared to machine-related sources.  Based on these results, fluence 
variation caused by machine-related sources is expected to be 1% on average and no 
greater than 5% in worst-case scenarios while the machine is still operating under 
tolerances.  Gross delivery errors could still happen due to machine-related failures, but 
these will easily be characterized as machine errors, not variability. 
3.2. Fluence Variation Caused by Patient-related Variability 
As mentioned, the other possible source of exit fluence deviations is from changes in 
the patient attenuation and scatter due to variations in the patient anatomy.  To 
investigate this source, a study was designed to quantify exit fluence variability caused 
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by changes in the patient geometry.  I utilized our in-house MC system and coded in 
additional functions as needed.  This system is described in the following section. 
3.2.1. Monte Carlo System 
The MC system used at our institution gives the user options regarding fluence 
generation, particle transport through the MLC, patient dose calculation, and DPI 
generation.  The incident fluence may be generated either by a phase space file 
representative of a full accelerator head simulation or from a source model (Fix, 
Stampanoni et al. 2001) that has been tuned to match our treatment machine.  For 
IMRT beams, particles are transported through the MLC using Siebers‘s method 
(Siebers, Keall et al. 2002).  Several patient dose calculation codes are coded into the 
system, including MCNP (Pacilio, Aragno et al. 2007), DOSXYZnrc (Walters, Kawrakow 
et al. 2005), and VMC++ (Kawrakow 2001).  After transport through the patient, the exit 
fluence is translated to the EPID location and a DPI is formed either using full MC 
simulation (Siebers, Kim et al. 2004) or via convolution with energy-dependent kernels 
(Wang, Gardner et al. 2009).  For the studies in this dissertation, the Fix source model 
was used as well as Siebers‘s MLC transport to generate the fluence incident on the 
patient.  Since VMC++ dose calculations have been validate against DOSXYZnrc at our 
institution (Gardner, Siebers et al. 2007; Gardner, Siebers et al. 2007), VMC++ was 
used for patient dose calculation and formation of the exit fluence.  The DPI was then 
formed via convolution of the fluence with energy-binned kernels. 
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Figure 11: Basic setup of our in-house MC system (on left), and the additions I made to it (on right). 
 
There were several additions I made to the library of codes, shown in Figure 11.  
I adapted the source model to allow for a simple point source (discussed in Section 
4.3.1) as well as a backprojected source (discussed in Section 4.1.3).   I also added in a 
particle handler which was useful for separation of the exit fluence into primary and 
scatter components.  Within the particle handler, upon being sourced, the direction and 
energy of each particle in the incident fluence was stored in random access memory.  
After transport through the patient/phantom geometry, the direction and energy of each 
exit particle was compared to the stored values of the incident particle.  If they agreed to 
within roundoff error, the particle was labeled a primary particle; if not, it was labeled a 
scatter particle.  For patient dose calculation, I scripted in the ability for the dose grid 
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resolution to be automatically set to the CT voxel resolution.  I found that this increase in 
resolution did not significantly affect the DPI calculation time, since per-pixel DPI 
uncertainty decreases at a slower rate than per-voxel patient dose uncertainty.  
Originally, the exit image (i.e. the convolved fluence) was the only output allowed.  I 
added the ability to score the fluence at the imager plane.  The fluence and DPI could 
now also be divided into primary and scatter fluences and images.  Finally, I added 
calculation of the uncertainty for both fluences and DPIs. 
3.2.2. Monte Carlo Calculations 
To examine the effect that changes in patient geometry have on the exit fluence, MC 
calculations were performed with identical source particles to ensure that no fluence 
deviations could be attributable to incident fluence variations.  The patient cohort used 
in this study was a dataset obtained from the NKI, which included nineteen prostate 
patients.  Each patient had from nine to fourteen FBCT acquisitions, which were 
acquired throughout the course of treatment delivery.  The CTs were rigidly registered 
to each other using bony anatomy landmarks using an in-house algorithm (Fatyga, 
Sleeman et al. 2012).  The first FBCT of each patient was treated as the planning CT, 
and plans were optimized on this geometry using the RTOG-0126 protocol (see 
planning objectives in Table 2).  A summary of the beam energy for each patient, as 
well as the number of non-planning geometries is shown in Table 3.  In ten patients, the 
plans were optimized with beam energy of 6 MV.  The remaining nine patients had 
plans optimized with 18 MV beam energy.  All plans included seven beams at beam 
angles of 30º, 80º, 130º, 180º, 230º, 280º, and 330º.   The GTV, rectum, and bladder 
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were manually contoured on each patient image by a single physician.  Since this 
database only involves the prostate site, the GTV was representative of the CTV. 
Table 2: Optimization objectives for the RTOG-0126 protocol.  A 0.5 cm margin was added around each structure for 
optimization.  The objectives are listed according to weight. 
ROI Constraint Type Target Dose (cGy) % Volume Weight 
CTV + 0.5 cm Min DVH 7920 98 100 
CTV + 0.5 cm Max DVH 8470 2 90 
Rectum + 0.5 cm Max DVH 6000 50 80 
Rectum + 0.5 cm Max DVH 6500 35 80 
Rectum + 0.5 cm Max DVH 7000 25 80 
Rectum + 0.5 cm Max DVH 7500 15 80 
Rectum + 0.5 cm Max Dose 8470  80 
Bladder + 0.5 cm Max DVH 6500 50 80 
Bladder + 0.5 cm Max DVH 7000 35 80 
Bladder + 0.5 cm Max DVH 7500 25 80 
Bladder + 0.5 cm Max DVH 8000 15 80 
Bladder + 0.5 cm Max Dose 8470  80 
L Femur + 0.5 cm Max DVH 3500 50 20 
L Femur + 0.5 cm Max Dose 5000  20 
R Femur + 0.5 cm Max DVH 3500 50 20 
R Femur + 0.5 cm Max Dose 5000  20 
 
Please note that, whereas my journal article detailed a single patient case, this 
dissertation work has expanded to a greater number of patients.  Also, the treatment 
plan detailed in the article differed in that the pelvic nodes were also included in the 
optimization process.  This led to larger fields, with greater complexity and higher 
intensity gradients.  All seven beams were split into two separate fields.  The plan was 
optimized with 18 MV energy beams. 
 38 
 
For each patient, the exit fluence was simulated through each of the patient 
geometries.  For each patient geometry, each beam sampled the exact same particles 
from the source model by using the same random seeds for source model input.  
Therefore, all differences in the DPIs could be attributable to patient anatomy changes 
and not to entrance fluence deviations.  For each DPI, 2.5×107 particles were sampled, 
yielding an approximate DPI statistical precision of one percent.  Average total 
calculation time per beam was approximately 25 minutes (distributed over ten 
processors).  Differences were computed between the simulated DPIs generated 
through each of the patient CTs.  The DPI per-pixel SDs (calculated over n patient 
geometries) were also computed for each beam for each patient. 
Table 3: Description of NKI patient database.  It included nineteen total prostate cases, ten of which were optimized 
with 6 MV beam energy. Not counting the first geometry, which was assumed to be the planning geometry, each 
patient had several more day-of-treatment fan beam CTs. 
Patient 
Beam 
energy 
Number of 
geometries 
 Patient 
Beam 
energy 
Number of 
geometries 
1 6 MV 11  11 18 MV 11 
2 6 MV 12  12 18 MV 13 
3 6 MV 11  13 18 MV 10 
4 18 MV 10  14 18 MV 10 
5 6 MV 12  15 18 MV 12 
6 6 MV 8  16 6 MV 12 
7 18 MV 11  17 18 MV 12 
8 6 MV 12  18 6 MV 11 
9 6 MV 11  19 18 MV 10 
10 6 MV 10     
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For the published study, a sample patient beam is shown in Figure 12, along with 
its corresponding pixel SDs (calculated over images from twelve patient geometries) 
and largest percent difference between two DPIs.  Per-pixel percent differences greater 
than 5% (with respect to maximum intensity) existed in 16 out of 154 simulated DPIs for 
this patient.  The largest calculated pixel SD was 2.5%, and the largest pixel percent 
difference between any two fields was 8.6%.  Visual inspection of the patient CT data 
showed that the primary sources of exit fluence deviations were changes in the patient 
anatomy that resulted in different radiological pathlengths through the patient for the 
source particles.  In some cases, this change in attenuation was caused by changes in 
the rectal filling.  When gas was present in the rectum, the intensity of the DPI increased 
behind the rectum.  In other cases, particularly in beams at gantry angles of 80º and 
280º, the edges of the beams became tangential with the patient‘s outer skin contour.  
Therefore, slight changes in the height of the patient‘s abdomen on the treatment table 
resulted in significant changes in beam attenuation length. 
 
Figure 12: Patient-geometry-related sources of fluence variability.  Panel (a) shows the exit fluence intensity for a 
beam simulated through the planning geometry.  Panels (b) and (c) show the histogram of the pixel SDs and the pixel 
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SD image for this beam simulated through twelve different patient geometries-of-the-day.  Panels (d) and (e) show 
the histogram and image of the largest percent difference between any two DPIs simulated on any two given patient 
geometries.  The deviations present on the left side of the field were caused by the presence or lack of gas in the 
rectum in each patient geometry.  The deviations on the right side of the field were caused by deviations in the patient 
contour on different patient geometries. 
 
 Results are show in Table 4 for the nineteen plans in which pelvic nodes were 
not included in the treatment plan.  Per-pixel differences greater than 5% existed in 935 
out of 1,442 simulated DPIs (64% of fields), and greater than 10% existed in 384 fields 
(26% of fields).  Maximum per-pixel SDs for each patient ranged from 1.8% to 12.7%.  
Differences were most pronounced in patients whose planning CT contained a large 
amount of rectal gas. 
 
Table 4: DPI variation caused by changes in the patient anatomy between the planning geometry and the day-of-
treatment geometry.  All differences were calculated with respect to maximum dose in the planning DPI. 
Patient 
Maximum 
difference (%) 
Maximum 
SD (%) 
 Patient 
Maximum 
difference (%) 
Maximum 
SD (%) 
1 26.0 7.5  11 8.4 3.1 
2 36.9 12.7  12 14.4 5.7 
3    13 10.4 4.2 
4 14.0 5.4  14 6.0 1.8 
5 12.6 4.2  15 8.1 2.2 
6 17.7 6.3  16 15.7 6.1 
7 10.5 4.2  17   
8 15.2 4.1  18 21.9 8.3 
9 18.8 8.0  19 8.1 3.4 
10 20.6 6.2     
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3.3. Comparison of Sources of DPI Deviations 
While machine-related sources of fluence variation resulted in maximum DPI pixel SDs 
of 1% and maximum deviations of 5%, patient anatomy-related sources resulted in 
maximum DPI pixel SDs over 12% and maximum deviations of 36%.  Exit fluence 
deviations caused by patient-geometry-related sources were greater than those caused 
by machine-related sources, within the limits of this study.  Tests with our delivery 
system indicate that per-delivery fluence variations caused by machine-related sources 
of variation are within the acceptable tolerances expected for patient treatment.  For our 
system, blind application of the backprojection assumption to determine the incident 
fluence for patient dose reconstruction is not justified.  Doing so would likely attribute 
patient-geometry-related sources of exit fluence deviations to incident fluence 
deviations—the wrong source. 
It should be noted, however, that gross delivery errors could happen as a result 
of machine failure, such as failure of plan transfer to the treatment machine or failure of 
MLC leafs to remain in tolerance.  Even though these gross delivery errors would 
exceed the deviations caused by patient anatomy variations, they would easily be 
characterized as machine-related errors due to the size and shape of the DPI deviation 
maps.  In cases where gross delivery occur due to machine failure, backprojection-
based dose reconstruction can be performed since the exit deviations are caused by the 
entrance deviations (as long as concurrent deviations caused by patient anatomy 
variations are insignificant in comparison). 
This work was limited to a prospective study of detecting and measuring exit 
fluence deviations.  Therefore, several other potential machine-related sources of 
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fluence variability have perhaps gone unmeasured.  These sources include variability 
caused by gantry and collimator angle variation.  For pretreatment verification these 
sources have not caused any problems in the past, since all measurements were 
acquired at gantry and collimator angles of zero degrees.  However, for through-patient 
verification, possible gantry sag and collimator rotation must be accounted for. 
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4. Exit Dosimetry for Closing the Loop of Image Guided Adaptive 
Radiotherapy 
―Closing the loop‖ of IGART refers to feeding back information from treatment delivery 
verification for purposes of affecting future deliveries.  The two basic methods studied in 
this work which yield delivery verification are comparison of simulated and measured 
DPIs, and comparison of planned and actual patient doses.  In this chapter, correlations 
between DPI deviations and patient dose deviations will be examined, and 
recommendations will be made as how dose verification should be performed. 
4.1. Patient Dose Deviation Simulations 
An intuitive means of patient dose delivery verification involves comparison of planned 
and delivered 3D patient dose maps and DVHs.  Direct patient dose comparisons 
circumvent challenges associated with correlating DPI deviations to patient dose 
deviations.  In this section, a method to reconstruct the patient dose is described, as 
well as its assumptions and limitations.  Correlation between DPI deviations and patient 
dose deviations is also examined. 
4.1.1. Planned Dose – Planning Geometry 
Standard treatment delivery involves 1) acquisition of a planning CT, 2) plan 
optimization on the planning CT to some predetermined objectives, and 3) subsequent 
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delivery of this plan to the patient for all fractions.  Between 2) and 3), beam parameters 
are transferred to the treatment machine‘s R&V system to ensure that planned beams 
are delivered throughout the treatment course.  The total planned dose to the patient is 
divided into a fractionation scheme to favor normal tissue sparing, and the summation of 
the fractional doses is assumed to equal the delivered dose.  Throughout delivery, it is 
assumed that changes in the patient geometry negligibly affect the dose delivered to the 
patient.  Setup uncertainties and patient geometric changes are ideally absorbed by 
margins placed around the target and other structures of interest.  This planned dose to 
the planning target volume (PTV) is said to be representative of the dose received by 
the patient‘s clinical target volume (CTV). 
To simulate the offsets of differing fractional patient poses, the nineteen patient 
NKI prostate database was utilized (a description of the database was given in Section 
3.2.2).  For this study, each acquired CT was treated as a separate ―fraction‖ of delivery.  
Each fraction was given equal weighting, and the delivered dose to each patient pose 
was calculated by: 
 
where D is the dose, P is the planning-geometry-optimized fluence incident on the 
fractional geometry GF, and nf is the number of fractional geometries obtained for the 
patient.  Note that the dose was not accumulated over all fractions, but instead each 
fraction was viewed as representative of a total treatment dose by multiplying it by the 
number of fractions.  For the planned dose, since the patient geometry is assumed to be 
unchanged, the dose was calculated on the planning CT, and then multiplied by nf as 
well. 
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The treatment plans were optimized to the high dose arm of the RTOG-0126 
protocol.  The optimization objectives are shown in Table 2.  The quality of plan 
optimization should have little effect on the comparisons made among the different 
patient poses, since each patient pose used the same plan which was optimized on the 
planning geometry. 
4.1.2. Delivered Dose – Time-of-Treatment Geometry 
As shown in chapter 3, the variation in patient geometry over the course of treatment 
delivery yields non-negligible changes in the exit fluence.  To determine the effect of the 
anatomic changes on the delivered dose, the dose for each image set was computed by 
impinging the same source particles from the fluence (optimized on the first CT) on 
each fraction‘s CT.  This was possible with the MC dose calculation system by ensuring 
that the same random seeds were set for each component of the simulation for each 
fractional delivery.  Using this correlated source model assured that all observed dose 
differences were caused by differences in the patient‘s anatomy.  These fractional 
doses were termed the true doses, as they reflected our best estimate of the delivered 
dose to the patient.  For each fraction, the true doses were then compared to the 
planned dose.  Differences between planned and delivered doses were caused by the 
patient geometry variation throughout the treatment course.  Results of this comparison 
will be shown after the next section as these doses are also compared with 
backprojected doses as described below. 
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4.1.3. Reconstructed Dose – Planning Geometry 
As shown in Section 3.3, dose delivery through a patient geometry that differs from the 
geometry used to predict the time-of-treatment DPI will result in differences between 
measured and predicted DPIs.  Even though for this in silico study, identical incident 
fluences were incident upon the differing daily poses, clinically, when deviations 
between predicted and measured DPIs are observed, several groups backproject the 
exit fluence through the patient geometry to estimate the patient dose (Steciw, 
Warkentin et al. 2005; Talamonti, Casati et al. 2006; Mans, Wendling et al. 2010).  To 
quantify the dose as predicted by backprojection, the following procedure was followed. 
The exit fluence corresponding with the planning geometry was calculated 
through the first acquired CT for each patient, as was the exit fluence through each 
fraction‘s geometry, termed the actual exit fluence.  The backprojection-based 
reconstructed patient dose was obtained in similar fashion to the true dose, except the 
incident fluence was multiplied by the ratio of the true exit fluence to the planned exit 
fluence: 
 
where DR is the reconstructed dose, P is the optimized fluence incident on GP, the 
planning geometry,  is the exit fluence calculated through each fraction‘s geometry, 
and  is the exit fluence calculated through the planning geometry.  The reconstructed 
dose was then compared to the true dose. 
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Figure 13: Demonstration of how the backprojection assumption could lead to erroneous dose reconstruction.  A 
planning target (red circle) is located inside a water phantom.  The planning fluence is incident on both the planning 
phantom geometry (left) and treatment phantom geometry (center).  An air gap which was not present in the planning 
geometry, has been introduced in the treatment geometry.  Due to less attenuation in the treatment geometry, the 
measured DPI has an area of higher intensity when compared to the expected DPI (estimated using the planning 
geometry).  In the backprojection assumption, the DPI deviation is attributed to the incident fluence.  Dose 
reconstruction will result in a higher estimated target dose, while the reconstructed DPI will agree with the measured 
DPI. 
It was hypothesized that, for patient cases, deviations between the reconstructed 
and true doses would be larger than deviations between the planning and true doses.  
The reasoning for this hypothesis is shown in the following thought experiment (shown 
in Figure 13).  Consider the planning geometry to be a solid water phantom, and the 
time-of-treatment geometry to be the same solid water phantom, except with a volume 
of air in the beam-line.  The CTV is located directly in front of where the air pocket 
exists.  The time-of-treatment measured exit fluence would be equal to the expected 
exit fluence except for the area directly behind the air pocket, which would have a 
higher intensity due to a lower attenuation pathlength through the air pocket.  For 
backprojection-based patient dose reconstruction, this deviation would be attributed 
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wrongfully to deviations in the incident fluence, which would be assumed to have an 
area of higher intensity.  The reconstructed patient dose uses an incident fluence with 
an area of higher intensity, and therefore the reconstructed dose would be elevated 
throughout the patient along the area covered by the higher intensity area.  While both 
the reconstructed and true doses for the CTV are higher than the planned CTV dose, 
the reconstructed dose also has higher dose in all normal structures along the beam as 
well.  While this is a simplified thought experiment, it indicates that caution must be 
exercised before blindly using fluence backprojection to achieve dose reconstruction. 
4.1.4. Planned, Actual, and Backprojected Dose Comparisons 
A simple metric to compare patient plans is the dose-volume histogram (DVH).  Indeed, 
DVH metrics are used as a basis for both plan optimization and plan approval.  DVHs 
for the GTV, rectum and bladder for each patient are shown in Figure 34-82 in Appendix 
II.  Respective zoomed-in GTV DVHs are shown are also shown in Appendix II.  Each 
plot includes the planning DVH as well as each day-of-treatment delivered and 
reconstructed DVHs.  Histograms of several GTV dose indices differences are shown in 
Appendix II also. 
 An example of a patient which showed minor deviations is patient 7 (Figure 52-
55).  The average reconstructed GTV D95 is 2 cGy less than the planned D95, while the 
average actual D95 is 38 cGy less than the planned.  If the plan were to be adapted to 
achieve the same exit fluence using dose reconstruction results, 2 cGy more dose 
would be delivered to the GTV D95.  This adaptation would result in the GTV D95 
absorbing 36 cGy less than the planned dose.  This correction would result in a slight 
improvement to the total target dose. 
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 A typical patient case is patient 13 (Figure 67-70).  The average reconstructed 
GTV D95 is 55 cGy greater than the planned D95, while the average actual D95 is 82 cGy 
less than the planned.  If the plan were to be adapted to achieve the same exit fluence 
using dose reconstruction results, 55 cGy less dose would be delivered to the GTV.  
This adaptation would result in the GTV absorbing 137 cGy less than the planned dose.  
Instead of improving the treatment, this correction would exacerbate the delivery. 
 The largest discrepancies between backprojected and actual doses happened in 
patient 4 (Figure 43-46).  The average reconstructed GTV D95 is 123 cGy greater than 
the planned D95, while the average actual D95 is 179 cGy less than the planned.  If the 
plan were to be adapted to achieve the same exit fluence using dose reconstruction 
results, 123 cGy less dose would be delivered to the GTV.  This adaptation would result 
in the GTV absorbing 302 cGy less than the planned dose. 
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Figure 14: Distribution of GTV D95 deviations for each patient.  Delivered versus planned deviations are shown by the 
blue triangles.  Backprojected versus planned deviations are shown by the purple x‘s.  The mean deviations between 
backprojected and delivered dose are shown by the orange circles. 
 
 For each patient, DVH deviation distributions between delivered and planned 
dose, as well as between backprojected and planned dose were calculated, along with 
the mean deviation between backprojected and delivered dose.  The dose indices 
examined were GTV D95 (Figure 14), bladder D25 (Figure 82) and D50 (Figure 83), and 
rectum D17 (Figure 84) and D35 (Figure 85) (only the GTV plot is shown in this chapter; 
all others are shown in Appendix II).  For the GTV D95, in some patients (patients 2 and 
12), the backprojected dose deviated more from the planned dose than the delivered 
dose.  In other cases (patients 13 and 14), the opposite held true: the delivered dose 
deviated more from the planned dose than the backprojected.  The backprojection-
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versus-delivered deviations show the effect that adaptation of the plan would have on 
the delivered dose.  Once again, in some cases the adaptation would bring the 
delivered dose closer to the planned dose, but in others it would push it farther away.  
The bladder and rectum plots show that while the backprojected dose stays within a few 
hundred cGy of the planned dose, the delivered dose varies up to 6000 cGy.  The 
difference in magnitude is due the fact that dose reconstruction was implemented on the 
planning geometry—the structures were in the exact same position for calculation of 
both planning and backprojected dose distributions.  The delivered dose, however, was 
calculated on each patient pose, yielding widely varying bladder and rectum doses due 
to their positional variance. 
 The relationship between exit fluence deviations and patient dose deviations was 
examined.  For each beam of each patient pose of each patient, the number of pixels 
with deviations greater than 5% was determined.  Only pixels with dose greater than 
20% max dose (i.e. those in the beam) were tabulated.  The fraction of pixels with 
deviations greater than 5% was then calculated for each patient pose of each patient 
geometry.  The deviation between delivered and planned GTV D95‘s were plotted 
against the DPI deviations (shown in Figure 15).  For each patient pose, the DPI 
deviation frequency was averaged over all beams.  Lines of best fit were plotted for 
each set of data (delivered minus planned, backprojected minus planned, backprojected 
minus delivered), and the null hypotheses was tested: that the slope of each line was 
equal to zero.  The null hypothesis was not rejected (p = 0.08) for the delivered-minus-
planned data; the slope of the data could be zero.  The null hypothesis was rejected for 
the backprojected-minus-planned data (p = 3.4×10-11) and the backprojected-minus-
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delivered data (p = 0.004).  In this instance, DPI deviations were positively correlated to 
DVH deviations. 
 
Figure 15: Deviation in GTV D95 versus fraction of DPI pixels that have deviations greater than 5%, for all NKI 
patients.  The diamonds correspond to differences between the delivered and planned doses.  The squares 
correspond to differences between the backprojected and planned doses.  The triangles correspond to differences 
between the backprojected and delivered doses.  Respective trend lines are shown.  For DPIs, only pixels with dose 
greater than 20% of maximum dose were analyzed.  For each patient pose, the DPI pixel deviation frequency was 
averaged over all beams.  
 
 It must be noted that the correlation between DPI deviations and DVH deviations 
is not always straightforward.  As seen in Figure 15, there are some patient poses which 
result in greater than 40% of DPI pixels having deviations greater than 5%, yet there is 
less than a 100 cGy GTV D95 difference.  Further examination of these patient poses 
reveals that DPI deviations were caused by variations in the amount of gas present in 
the rectum (see Figure 16).  Since beam attenuation through gas is much less than that 
through tissue, the difference between the planned and delivered DPIs was greater than 
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5% in the area behind the presence of rectal gas.  However, the location of the rectal 
gas did not cause significant differences between the planned and delivered target 
dose.  In a few observed patient poses, however, the GTV location was shifted past the 
limits of the PTV due to variation in bladder filling (see Figure 17).  In this case, even 
though the GTV D95 deviation was greater than 500 cGy, there were no DPI deviations 
greater than 5%.  In these cases, variation in bladder filling did not significantly affect 
the patient attenuation. 
 
Figure 16: Coronal slice through the planning pose (left) and a day-of-treatment pose (right).  The rectal gas present 
in the day-of-treatment pose causes DPI deviations greater than 5% from expected.  However, the GTV D95 deviation 
is less than 100 cGy. 
 
Figure 17: Coronal slice through the planning pose (left) and a day-of-treatment pose (right).  The filling of the 
bladder in the day-of-treatment pose causes the prostate to shift inferior to isocenter, and therefore the GTV D95 
deviation is greater than 500 cGy.  However, there are no large patient attenuation differences caused by bladder 
filling, and therefore the DPI deviations are less than 5% in all pixels. 
To further examine the efficacy of using DPI deviations to predict DVH deviations 
a receiver operating characteristic (ROC) curve was generated.  The percentage of 
failing DPI pixels (i.e. those with deviations greater than 5%) was used as the 
independent variable.  For each patient pose, the GTV D95 deviations were deemed 
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positive or negative based on whether or not they exceeded doses of 50 cGy, 100 cGy, 
150 cGy, and 200 cGy.  If the DVH deviation exceeded the dose deviation criterion, it 
was considered a true or false positive (TP or FP), (true if the DPI deviations were a 
correct predictor, false if the DPI deviations were an incorrect predictor).  If the DVH 
deviation did not exceed the dose deviation criterion, it was considered a true or false 
negative (TN or FN).  The true positive rate (TPR) and false positive rate, defined as: 
TPR = TP / (TP + FN) 
FPR = FP / (FP + TN) 
were plotted against each other to form ROC curves for each dose deviation criterion.  
The ROC curves are shown in Figure 18.  A measure of predictive accuracy was 
obtained by measuring the area under each curve (AUC)—equaling 0.58 for the 50 cGy 
criterion, 0.63 for the 100 cGy criterion, and 0.55 for both the 150 cGy and 200 cGy 
criteria.  None of the criteria yielded an acceptable predictive quality, as an AUC of 0.63 
was not sufficient. 
 One method to correct for the false positives (e.g. significant DPI deviations, but 
insignificant DVH deviations) involves limiting rectal gas via dietary protocol.  In fact, the 
NKI recommends a dietary protocol of mild laxatives two days prior to imaging or 
treatment (Smitsmans, Pos et al. 2008).  This protocol resulted in less random 
interfraction prostate motion.  A method to correct for the false negatives (e.g. 
insignificant DPI deviations, but significant DVH deviations) would be to use implanted 
markers in the target.  Due to their higher electron density, these markers will alter the 
attenuation through the patient such that they are visible in the DPI.  Thus, the 
positioning of the target may be monitored with the EPID.  Also, other target-monitoring 
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devices could be used to assure that the target has not significantly shifted between 
planning and delivery.  Detection of implanted markers is discussed in the following 
section. 
 
 
Figure 18: ROC curve showing the predictive value of DPI deviations for GTV D95 deviations with tolerance criteria of 
50 cGy, 100 cGy, 150 cGy, and 200 cGy.  The dotted black line is the line y = x. 
4.2. Detection of Implanted Markers 
The proposal for this work called for both time-of-treatment CTs and DPIs to be 
acquired for patients at our institution for the prostate site.  Only two patients enlisted in 
the prostate protocol at our institution.  This protocol included acquisition of a CBCT 
while the patient was on the delivery couch, as well as acquisition of DPIs for every 
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treatment beam.  The protocol also called for Calypso (Seattle, WA) marker implants to 
monitor prostate positioning throughout treatment delivery.  Therefore it was of interest 
as to whether the markers could be detected in measured DPIs for each beam. 
Before any patients went through the protocol, an experiment was designed to 
determine whether the EPID could detect objects of similar size to Calypso 
transponders.  While measured exit fluence images can detect the presence of changes 
in the patient geometry, they do not necessarily provide a quantitative description of 
what those changes are.  If objects such as fiducial markers are implanted at precise 
locations within the patient geometry, it may be possible to locate them in the exiting 
fluence due to their higher attenuation coefficients as compared to the surrounding 
normal tissue.  The detection of these objects in the measured exit fluence image 
provides insight into target location changes during treatment, which is critical for 
achievement of dose verification.  At our institution, the Calypso system has been 
installed to monitor patient position variations during treatment delivery.  
Electromagnetic transponders are implanted in the patient and transmit safe 
radiofrequency waves which are detected by the Calypso receptor and processed to 
determine transponder position.  Thus, patient anatomic positional information is gained 
during treatment delivery.  Although these transponders have a lower atomic density 
than gold fiducial markers, they should still be visible in a DPI due to their higher density 
as compared to surrounding tissue.  If the transponders can be detected in a DPI, then 
this provides an opportunity to correlate Calypso‘s positioning measurements with those 
determined using the DPI.  For patient plans which do not employ the Calypso system, 
implanted gold fiducial markers may be used for patient setup, alignment, and 
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monitoring.  Localization of the markers on the measured DPI will provide knowledge of 
the patient geometry during treatment. 
For IMRT treatments, identification of markers in DPIs is confounded by patient 
scatter, fluence fluctuations caused by the IMRT delivery, and tissue heterogeneities in 
the patient.  Distinguishing the markers from background becomes difficult due to the 
widely varying levels of intensity incident on the patient.  To obtain a DPI in which the 
objects may be located, a ratio may be taken between the DPI with the patient present 
and the DPI without the patient present.  With the patient present, the fluence incident 
on the EPID could be described as: 
0 ( )patient MLC patientA A S  
where 0  is the fluence exiting the accelerator, MLCA  is the attenuation due to the MLC, 
patientA  is the attenuation due to the patient, and S  is patient scatter.  Without the patient 
present, the fluence incident on the EPID could be described as: 
0no patient MLCA  
Solving for the attenuation due to the patient, the following equation is obtained: 
0patient
patient
no patient no patient
A S  
To examine whether an object the size of a transponder could be distinguished 
on a DPI of an IMRT field, two standard gold markers were positioned near the prostate 
location in a Rando (The Phantom Laboratory, Salem, NY) anthropomorphic pelvic 
phantom.  DPIs of the IMRT field were acquired both with and without the phantom 
present in the beam at a gantry angle of 0º.  A simple ratio (which assumes no scatter) 
was then calculated between the two images, yielding the attenuation map from the 
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phantom.  As seen in Figure 19, both gold markers were distinguishable in the ratio 
image in areas of both high and low beam intensity.  Future work in this study will be to 
subtract the estimated scatter from the patient/phantom geometry before the ratio is 
calculated.  The addition of a scatter filter to the algorithm should cause the markers to 
be much more distinguishable.  Also, pre-existent code in our institution that 
automatically detects markers will be used to automate the detection process (Murphy 
and Todor 2005). 
 
Figure 19: Ratio images of DPI with anthropomorphic phantom in the beam and without the phantom in 
the beam.  The left image corresponds to an accelerating potential of 6 MV, whereas the right image 
corresponds to an accelerating potential of 18 MV.  The gold markers are circled. 
 
4.2.1. EPID/Calypso Interference 
Once the DPIs were obtained for the first fraction of the first patient approved for the 
prostate protocol, it was immediately apparent that a significant artifact existed in the 
images.  The artifact appeared to be caused by an errant readout from the EPID imager 
due to the presence of vertical stripes through the images (see Figure 20).  It was 
hypothesized that the artifact was caused by electronic interference between the EPID 
 59 
readout system and the Calypso transponders which were implanted in the patient‘s 
prostate.  Supporting this hypothesis was the fact that the artifact grew worse when the 
EPID was closer to the Calypso receiver used for locating the position of the 
transponders.  The artifact was most noticeable when the gantry was at 180º, i.e. when 
the EPID was at its highest position, and closest to the Calypso detection panel.  The 
artifact was least noticeable when the gantry was farthest from 180º (for treatment 
beams at gantry angles of 30º and 330º). 
 
Figure 20: Example of a through-patient DPI captured during treatment of a prostate site.  The gross artifacts, 
present both inside and outside the field, were unexpected.  It was hypothesized that the artifacts were caused by 
interference between the Calypso transponders located in the patient‘s prostate and the readout electronics of the 
EPID.  The gantry angle for this DPI was 180º. 
 
 To test this hypothesis, reproduction of the artifact was attempted in a controlled 
setting.  A set of Calypso transponders was borrowed from our clinic, and placed upon 
the treatment couch, with the Calypso detection panel in its proper place, located above 
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the couch.  The gantry was rotated to 180º, and the EPID was extended above the 
Calypso panel at SDDs ranging from 125 cm to 150 cm.  Control images of two fields (a 
flood field and a 10×10 cm2 field) were acquired while the Calypso monitoring remained 
inactive.  Test images were then acquired with the Calypso monitoring active.  A ratio of 
the active to inactive Calypso images for the 10×10 cm2 field is shown in Figure 21.  
Differences as large as an order of magnitude were seen outside of the field.  An 
indirect relationship was confirmed between the artifact severity and distance between 
the EPID and Calypso panel. 
 It was hypothesized that this artifact could be removed by constructing a Faraday 
cage around the EPID to remove any electronic interference from the Calypso panel.  
The same measurements described in the previous paragraph were re-acquired, except 
with a rudimentary Faraday cage protecting the EPID.  The cage was constructed out of 
overlapping pieces of aluminum foil wrapping around the outer shell of the EPID.  As 
shown in Figure 22, the severity of the artifact was reduced by an order of magnitude.  
Profiles across the left-right and inferior-superior directions are shown in Figure 23 and 
Figure 24.  Even with the reduction of the artifact, they were still too large to detect the 
implanted transponders.  Therefore, no more measurements were analyzed for the 
dose verification study. 
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Figure 21: Ratio of the 10×10 cm
2
 field acquired with active Calypso tracking to that without Calyspo tracking.  The 
field is marked by the dashed black line.  Artifacts as large as an order of magnitude are seen outside the field. 
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Figure 22: Ratio of the 10×10 cm
2
 field acquired with active Calypso tracking and a rudimentary Faraday cage 
surrounding the EPID to that without Calypso tracking or Faraday cage.  Artifacts were reduced by an order of 
magnitude outside of the field.  Deviations along the field edges were due to slight variation in the jaw positions 
between acquisition of the two DPIs. 
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Figure 23: Profile along the left-right direction for a 10×10 cm
2
 field for a non-Calypso/non-Faraday cage set-up 
(green line), a Calypso/non-Faraday cage set-up (blue line), and a Calypso/Faraday cage set-up (red line).  The 
green line represents normal acquisition of a DPI.  The blue line represents the artifact caused by electronic 
interference between the EPID readout and Calypso transponder tracking.  The red line represents the correction for 
the artifact by enclosing the EPID in a rudimentary Faraday cage.  The ―ripples‖ in the middle of the profile are 
caused by attenuation of the case containing the transponders on the couch. 
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Figure 24: Profile along the superior-inferior direction for a 10×10 cm
2
 field for a non-Calypso/non-Faraday cage set-
up (green line), a Calypso/non-Faraday cage set-up (blue line), and a Calypso/Faraday cage set-up (red line).  The 
green line represents normal acquisition of a DPI.  The blue line represents the artifact caused by electronic 
interference between the EPID readout and Calypso transponder tracking.  The red line represents the correction for 
the artifact by enclosing the EPID in a rudimentary Faraday cage. 
 
4.3. DRR Simulations 
Closing the loop of IGART via DPI comparison requires accurate simulation of the 
expected DPI.  Sensitivity of comparisons should increase as the amount of time 
decreases between the image used for DPI simulation and the treatment time DPI 
measurement as there is less time for the patient to change.  Depending on the clinic 
and patient protocol, the most recent patient geometry could range from the planning 
FBCT (taken several days in advance) to a CBCT acquired moments before the 
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treatment delivery begins.  Therefore a balance must be struck between the accuracy 
and the speed of DPI simulation. 
In non-time critical situations, MC simulation of radiation transport to 
simultaneously determine patient dose and the exit fluence DPI provides an accurate 
method to perform delivery verification.  However, dose calculation for online IGART 
treatment evaluations is not feasible with pure MC techniques due to computation time.  
Nonetheless, in these cases post-treatment delivery validation can be performed when 
daily treatment adaptations occur.  This process, however, only permits offline closed 
loop adjustments.  Greater speed DPI calculations are required for online IGART. 
A through-patient DPI consists of two fluence components incident upon the 
EPID: 1) the attenuation of the incident fluence through the patient, termed DPIatt, and 
2) the scattered radiation produced within the patient, termed DPIscat.  The DPI 
calculation is therefore separable, and each component has the potential to be 
computed using faster techniques.  An estimate of DPIatt may be obtained by calculating 
the attenuation along the ray through the patient geometry to each detector pixel.  
These calculations are called digitally reconstructed radiographs (DRRs).  An estimate 
of DPIscat component may be obtained from MC models, if there is low variation of the 
component caused by variation in patient anatomy.  This section describes 
development of DRR-based DPI calculations, with MC calculation through the same 
geometries used as a reference standard. 
4.3.1. DRR Calculation 
A DRR patient attenuation model was created by modifying an in-house DRR algorithm.  
Inputs for the original in-house DRR code include 1) the source definition, which is 
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taken to be a mono-energetic point source, 2) the patient CT geometry through which 
the incident source fluence is projected, and 3) the detector geometry, which is a simple 
plane of pixels.  The original DRR generator ray traced through the patient geometry 
from a point source located at the accelerator target location.  In performing the ray 
trace, the provided code simply added pathlengths through the geometry as opposed to 
computing exponential attenuation.  Siddon‘s technique was used for ray tracing 
(Siddon 1985). 
This in-house DRR code was adapted for calculating the primary transmission of 
a megavoltage beam through a patient geometry.  Three major changes were 
implemented.  First, the code was updated to handle poly-energetic beams as input by 
using a fluence-weighted sum of mono-energetic calculations.  For both 6 MV and 18 
MV accelerating potentials, the beam energy spectra were modeled according to Mohan 
(Mohan, Chui et al. 1985), with energy bins of 0.5 MeV.  Secondly, the patient CT was 
transformed from CT-number information to meaningful attenuation information, i.e. , 
where  is the mass attenuation coefficient and  is the density of the voxel material.  
Since  is dependent on beam energy, per-energy-bin instances of the patient geometry 
were created.  The per-energy values of  were derived using XCOM (Berger, Hubbell 
et al. 1998), a photon cross sections database provided by the National Institute of 
Standards and Technology (NIST).  Finally, the model for attenuation was updated from 
an additional to an exponential one. 
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Figure 25: Irregular phantom created for geometric validation of the DRR model.  The incident beam, directed into 
the page, is shown in yellow. 
 
Figure 26: DRR-generator GUI.  The GUI is used to set options describing the geometry of the beam, phantom, and 
imager, based on a user-selected input file (seen in top left).  The ―Calculate DRR‖ button is then pressed, which calls 
the DRR simulation code to run.  The generated DRR is then displayed in the panel on the right. 
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Primary attenuation for the DRR-based DPI-generator was benchmarked via 
comparison with an MC-generated exit fluence (discussed in Section 3.2.1).  I coded in 
the ability to separate the MC-generated exit fluence into primary and scatter 
components, permitting this comparison.  For the MC calculations, instead of using the 
full head source model, a simple point source was coded by changing the directional 
components of each sourced particle and forcing them to have the same origin at the 
target location (0,0,0), thereby allowing for comparison to the simple DRR point source.  
To verify that the geometry of the DRR was consistent between the DRR and MC codes 
(i.e. the patient geometry and scoring plane were in the correct position relative to the 
point source), an irregular water phantom was created and is shown in Figure 25.  
Delivery information stored in the TPS was transferred manually to both the DRR and 
MC codes for input.  This information included beam energy, patient/phantom geometry, 
and imager geometry.  One billion photons were simulated incident on the testing 
phantom for the MC calculation, which required slightly less than three hours of 
computer time (on a single CPU).  DRR-generation required approximately one minute 
(on a single CPU), of which the majority was spent loading the phantom geometry into 
the code system.  The DRR calculation itself took less than ten seconds.  The graphical 
user interface (GUI) for the DRR generator is shown in Figure 26. 
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Figure 27: Comparison of DPIs simulated through an irregular water phantom by the primary component of an MC 
calculation (top left) and by a point-source DRR calculation (bottom left).  The difference map, measured in percent 
with respect to maximum intensity, is shown in the top right panel.  Profile intensities along the dashed black line of 
the images are shown in the bottom right panel.  The blue data refers to the MC-generated DPI, while the green data 
refers to the DRR-generated DPI.  
 
The DRR- and MC-generated images are compared in Figure 27.  Differences up 
to ten percent of maximum intensity were observed along the edges of the irregular 
phantom.  While the MC-generated image showed a softer gradient in these areas, the 
DRR-generated image displayed very sharp edges.  In low-gradient areas, however, the 
DPIs agreed within two percent.  It was shown that the TPS information was 
successfully transferred to the DRR system, and that the DRR-generator correctly 
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modeled the geometry of the beam, patient, and imager.  Planned future development 
of the DRR code includes IMRT capabilities and a more fully automated system. 
4.3.2. Patient Scatter Model 
It was hypothesized that patient exit scatter variation was insignificant with respect to 
the total exit fluence, and therefore a single scatter estimate would be valid for all 
patient poses.  An estimate of the patient scatter contribution to the exit fluence was 
obtained by using MC simulations to compute the scatter contribution to the exit fluence 
for each image of each patient from the NKI prostate patient database (described in 
Section 3.2.2).  Since the VMC++ MC code used in this study does not have a ―latch bit‖ 
(which, in other MC codes, defines the geometry of last interaction for each particle), a 
module was written which enabled separation of primary and scatter components.  First, 
the MC source model was modified to bank particles to an exit particle handler.  This 
consisted of saving the phase space coordinates of the source model particle.  Phase 
space coordinates (u,v,w) of particles exiting the MC patient geometry were compared 
to those of the source model particle.  If the energy and direction differed by less than 
round-off error, the particle was labeled a primary particle; if not, the particle was 
labeled as scatter.  The exit scatter fluence was then convolved with the EPID fluence-
to-dose energy deposition kernels at the imager surface to produce the scatter DPI.  
The per-pixel standard deviation of these DPIs was then calculated over the set of all 
geometries for each patient.  This scatter variation was then divided by the maximum of 
the mean total DPI (primary plus scatter), to determine the significance of the variation 
in the scatter component as compared to the total DPI. 
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For a single patient case, plots of the scatter variation, both by itself and 
compared to maximum mean total dose, are shown in Figure 28.  For this patient, DPIs 
were simulated through eleven geometries.  The per-pixel relative standard deviation of 
the scatter component for each beam ranged up to 8% of the scatter DPI imager dose.  
When compared to the maximum total imager dose for each beam, however, the impact 
of the scatter variation is minimal: for this patient, it is less than 0.2%.  The mean and 
maximum per-pixel scatter variations (with respect to total imager dose) for each patient 
are shown in Table 5.  The mean per-pixel scatter variation with respect to total dose 
was averaged over all beams for each patient, while the maximum per-pixel variation 
was determined over all beams as well.  The largest mean scatter variation was on the 
order of 0.1%, and the largest maximum scatter variation was on the order of 0.6%. 
Table 5: Mean and maximum per-pixel standard deviations for the scatter component of the exit image.  These 
values were calculated with respect to maximum total dose.  The mean scatter variation for each patient was 
averaged over all beams, while the maximum scatter variation was found over all beams. 
Patient 
Mean scatter 
variation (%) 
Max scatter 
variation (%) 
 Patient 
Mean scatter 
variation (%) 
Max scatter 
variation (%) 
1 0.12 0.41  11 0.07 0.20 
2 0.11 0.40  12 0.07 0.21 
3 0.13 0.60  13 0.05 0.15 
4 0.05 0.15  14 0.06 0.19 
5 0.11 0.51  15   
6 0.10 0.33  16 0.11 0.37 
7 0.07 0.21  17   
8 0.09 0.25  18 0.14 0.46 
9 0.11 0.41  19 0.08 0.23 
10 0.14 0.47     
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Figure 28a: Scatter variation for patient 1, scaled in percentages.  The left column shows the per-pixel relative 
standard deviation of the scatter DPI through a series of eleven patient geometries.  The right column shows the 
same scatter variation, but in relation to the maximum mean total DPI.  Only the DPI area within 2 cm of the beam is 
included.  Gantry angles of 180º, 230 º, 280 º, and 330 º are shown on the following pages. 
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Figure 13b: Scatter variation for patient 1, scaled in percentages.  The left column shows the per-pixel relative 
standard deviation of the scatter DPI through a series of eleven patient geometries.  The right column shows the 
same scatter variation, but in relation to the maximum mean total DPI.  Only the DPI area within 2 cm of the beam is 
included.  Gantry angles of 30º, 80 º, 130 º, and 330 º are shown on the previous and following pages. 
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Figure 13c: Scatter variation for patient 1, scaled in percentages.  The left column shows the per-pixel relative 
standard deviation of the scatter DPI through a series of eleven patient geometries.  The right column shows the 
same scatter variation, but in relation to the maximum mean total DPI.  Only the DPI area within 2 cm of the beam is 
included.  Gantry angles of 30º, 80 º, 130 º, 180 º, 230 º, and 280 º are shown on the previous pages. 
 
For all patients, the scatter variation of the DPI was observed to have 
insignificant impact (less than 0.2%) when compared to the total intensity of the DPI, as 
shown in Table 5.  Therefore, when simulating a DPI by combining a DRR calculation 
with a scatter component, it is unnecessary to estimate the scatter through each 
individual patient geometry.  Since scatter variation is a insignificant with respect to 
fluence variations caused by changes in the patient geometry, the scatter component of 
the exit fluence for a patient pose can be estimated by the MC-derived scatter 
component of the planning geometry exit fluence.  Addition of the planning exit scatter 
fluence to the day-of-treatment DRR-generated primary exit fluence yields an estimate 
of the expected during-treatment exit fluence, which will be compared to the per-beam 
DPIs measured during each fraction of treatment delivery. 
4.4. Significance of Findings 
Since there was positive correlation between the DVH deviations and DPI deviations, 
there is potential to reduce patient dose reconstruction errors caused by the 
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backprojection assumption.   For this dataset, the amount of time that elapsed between 
acquisition of the planning CT and day-of-treatment CT images varied from a few days 
to several weeks.  Exit fluence deviations caused by changes in patient geometry 
should decrease as the time between imaging and treatment decreases.  In an ideal 
situation, the patient would be imaged as the treatment is delivered, thereby giving 
complete knowledge of the geometry through which dose is delivered and the DPI is 
acquired.  In this case, the delivered dose could be reconstructed with no errors 
introduced by the backprojection assumption. 
Although it is currently unfeasible to image the patient during treatment, it is 
possible to image them immediately prior to treatment delivery.  Some delivery systems 
have a CBCT system for pretreatment imaging.  Acquiring a CBCT of the patient 
immediately prior to treatment delivery—and using that geometry for backprojection—
would reduce the exit fluence deviations caused by assuming the backprojection 
geometry is the same as the planning geometry.  However, exit fluence deviations, 
although reduced, will persist due to changes in the patient geometry between 
acquisition of the CBCT and delivery of the treatment immediately thereafter. 
One disadvantage of imaging the patient before each fraction of delivery is the 
extra dose that this CT imaging causes.  A daily CBCT would not be necessary for a 
patient geometry which does not vary significantly from fraction to fraction.  In these 
cases, generating DPIs through previous patient geometry incidences should suffice for 
treatment verification.  A potential application of this work in exit fluence dosimetry is to 
set tolerance levels for exit fluence deviations such that if deviations exceed the level, 
then the patient should be re-imaged immediately after treatment delivery. 
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Differences between expected and measured DPIs will always exist because 1) 
the patient geometry always deforms both inter- and intrafractionally, and 2) the beam 
characteristics have an inherent variation.  Thresholds theoretically can be determined 
which will distinguish between clinically significant and insignificant deviations.  Based 
on these tolerances, it will be possible to predict when exit fluence deviations indicate 
significant deviations between the planned and delivered patient doses.  Thus, dose 
verification will be performed.  However, as has been shown by my backprojection-
based dose reconstruction, misattributing a source of exit fluence deviation may result 
in a poorer estimate of the patient dose.  Therefore, it is critical to determine the source 
of DPI deviations to judge not only how delivery verification should be performed, but 
also whether the delivery was within tolerance. 
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Figure 29: Decision tree showing how to process DPI deviations.  If the differences are insignificant, dose 
reconstruction is performed to achieve delivery verification.  If the differences are significant, the source of the 
differences is determined by comparing the deviation map with a bank of known deviations.  This comparison will 
show whether the differences were caused by changes in the patient geometry, changes in the machine-delivered 
fluence, or a combination of the two. 
 
 To address this, a decision tree for how to deal with DPI deviations was 
developed and is shown in Figure 29.  The process begins with simple comparison of 
the measured and expected DPIs.  If significant differences do not exist, then patient 
dose reconstruction may be performed if the physicist desires to analyze DVHs.  If 
significant differences do exist between the measured and expected DPIs, further action 
is required.  The process continues with classification of the deviation according to its 
source by comparison with respect to a library of previously-known deviation maps and 
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probably sources of error.  When the comparison shows that the deviations were 
caused by changes in the machine-delivered fluence, then the expected DPI should be 
re-simulated using the entrance fluence formed by the MLC leaf positions which were 
recorded during treatment (in files called ―dynalogs‖).  When the deviation is attributed 
to patient anatomical changes, a better estimate of the patient geometry is necessary, 
either by re-imaging the patient or adjusting the prior image before dose evaluation.  If 
the deviation map is dissimilar to any in the library of known deviations, the patient 
geometry should be examined to find the sources of the differences.  Once the source is 
determined, it will be added to the library of known deviation maps for future matching 
purposes.  The patient dose may then be reconstructed with a known uncertainty.  If the 
uncertainty is significant, then dose reconstruction-based delivery verification will not be 
performed. 
 Correlation between DPI and DVH deviations must be further examined to obtain 
a more accurate predictor of treatment delivery failure.  In this work, the only predictor 
examined was frequency of DPI pixel deviations greater than 5%, which resulted in an 
ROC curve showing accuracy of only 0.63.  To increase this accuracy, combinations of 
other DPI deviation characteristics should be examined, such as greater or lower DPI 
deviation thresholds, or areas of DPI deviations.  An increase in predictor accuracy is 
necessary for DPI-based dose verification to be effective. 
 This study was limited to the prostate site, where typical patient anatomy 
variations include bladder and rectal filling.  Correlation between DPI and DVH 
deviations should also be examined at different sites such as H/N and lungs, where 
heterogeneity is more prevalent, leading to a higher variation in patient attenuation.  
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DPI-based verification should detect shrinkage of H/N tumors over the treatment 
course, as well as changes in the target size and shape in lung tumors over the 
treatment course. 
 The final step of closing the loop of IGART is development of a system which 
calculates the DPI deviations, evaluates whether the deviations are within tolerance, 
and recommends how to proceed.  This system should be located in the treatment 
control room, where the user will be able to monitor the reported deviations and have 
the option of stopping treatment if necessary.  The development of this tool is discussed 
in the following chapter. 
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5. Dose Verification Graphical User Interface 
Although there are several commercial EPID-based dose verification products, no 
existing product met the specific needs of this research study.  For example, Varian 
(Palo Alto, CA) offers a ‗PortalVision‘ tool whose image prediction algorithm is based on 
Van Esch‘s work (Van Esch, Depuydt et al. 2004).  PortalVision allows for comparison 
of measured and simulated portal images; however, it is limited to pretreatment 
verification (i.e. no patient in the beam) and bases its image analysis on Low‘s gamma 
metric (Low and Dempsey 2003).  Another product is available from Standard Imaging 
(Middleton, WI); however, it utilizes pretreatment fluence measurements to reconstruct 
dose on the patient‘s planning image.  Deconvolution of the portal image yields the 
incident fluence, which is then used to simulate the delivered patient dose on the 
planning patient geometry.  Verification is achieved when this ‗delivered‘ patient dose is 
compared to and agrees with the planned patient dose within tolerance.  In addition to 
commercial products available, several institutions have produced in-house verification 
tools for their own clinics (van Zijtveld, Dirkx et al. 2006; Mans, Wendling et al. 2010).  
The goal of this work is to provide our clinic with an in-house EPID-based verification 
tool, to be used for both pretreatment and, eventually, during-treatment delivery 
verification. 
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5.1. Current Clinical Practice 
IMRT treatments were implemented at VCU in 1998.  The original method used for 
pretreatment IMRT QA was purely radiographic film-based.  Starting in 2000, an 
independent MC calculation was also performed.  Film was replaced with the EPID in 
2003, while MC simulation continued.  This previous EPID-based system was 
qualitative in nature—the physicist would simply use a naked-eye determination of 
whether the field was adequately delivered.  Starting in 2009, the EPID-based system 
was replaced with one using an I‘mRT Matrixx (IBA Dosimetry America, Bartlett, TN) 
two-dimensional array of ionization chambers.  This device has 1020 ionization 
chambers spaced out over an area of 24.4 × 24.4 cm2, providing a resolution of 0.8 cm.  
During pretreatment verification, the Matrixx is placed on the treatment couch to capture 
the measured beams.  The measured images are then automatically imported to a 
verification GUI, which compares measured and expected images using the gamma 
metric (3%, 3 mm).  Since the DTA tolerance is less than the resolution of the Matrixx, 
the measured images are interpolated for gamma calculations.  For each field the GUI 
shows both the measured and expected image, a profile through the images, and the 
resulting gamma comparison image.  A printout is obtained from the GUI containing 
these images along with the gamma statistics, treatment and patient information, and 
appropriate signature lines (see Figure 30). 
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Figure 30: Sample printout from the I‘mRT Matrixx verification system.  The expected and measured fields are 
displayed on the left side, while the right side shows both a user-selected profile across both images, as well as the 
gamma comparison image.  Treatment plan information is displayed at the bottom along with gamma results and 
appropriate signature lines. 
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Utilizing the Varian aS1000 EPID instead of the Matrixx allows for improvements 
in delivery verification in several areas.  Physically, the EPID has a detection area that 
is twice as large (40 × 30 cm2) as the Matrixx, and a resolution that is up to twenty times 
higher (0.04 cm).  The EPID is also attached to the gantry, and may be automatically 
positioned and retracted from the control room, avoiding the time required to manually 
position the Matrixx for each verification session and allowing QA to be performed using 
treatment settings (e.g. gantry angle, collimator angle, etc…).  The motivation for 
changing to an EPID-based verification system is to allow QA of larger treatment fields, 
detection of smaller treatment delivery errors (due to the higher resolution), and ideally 
implementation of a speedier process. 
5.2. GUI-based Tool 
Both a clinical and an expert/research version of the delivery verification tool were 
created using MATLAB (MathWorks, Natick, MA).  For the clinical version, emphasis 
was placed on simplicity of the user interface and speed, qualities which would be both 
necessary and beneficial to improve efficiency in the clinical verification process.  For 
the research version, more options are available to the user for preprocessing of the 
images as well as more comparison metrics to allow for judgment of verification. 
5.2.1. Clinical Version 
The interface for the clinical version of the tool is shown in Figure 31.  When operating 
the clinical version of the verification GUI, the user first selects the directories for both 
the calculated expected images and the measured images.  Once the directories have 
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been selected, all images are automatically detected in each directory. The GUI is able 
to import several image formats: 
 DICOM (Digital Imaging and Communications in Medicine) – The record and 
verify system used at our clinic exports measured images in this format. 
 dxf (Drawing Interchange Format) – Another format for exported measured 
images through our record and verify system. 
 hna – The format used when acquiring images in the service mode with IAS 
Monitor. 
 binary MC – our in-house MC system simulates EPID images which use this 
binary storage format. 
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Figure 31: EPID-based delivery verification GUI designed for clinical use.  The expected image is displayed in 
the upper left panel, while the measured image is displayed in the upper right panel.  The resulting gamma 
comparison image is displayed in the lower right panel.  Buttons in the lower left panel allow for scrolling among 
all of the fields for a given patient, as well as printing out the QA report for the patient.  The table shows the 
gamma results for each field, as well as whether the field passed or failed the given criteria (in this case, a 3 mm 
distance-to-agreement and a 3% dose difference). 
 
Ideally, for every measured image in the measured directory, there is a 
corresponding calculated image in the calculated directory.  If this is not the case, the 
GUI reports that image(s) are missing from the appropriate location(s).  The GUI then 
populates a list of all images that are located in both directories and imports them.  The 
user may then scroll through and visualize each pair of images.  The GUI uses header 
information from each image to automatically adjust for imager location and resolution. 
 The next step of the verification process is for the user to click the ―Compare All 
Images‖ button, which performs a gamma comparison between the two images.  The 
default criteria for passing gamma at our clinic is 
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Where P is the percentage of pixels with gamma values less than 1 (i.e. passing 
gamma) for criteria of 3 mm distance-to-agreement and 3% dose difference.  Gamma 
values are only calculated for pixels with intensity greater than 20% of maximum pixel 
intensity.  The gamma calculation requires approximately five seconds per field.  After 
the calculations are finished, the gamma image is displayed next to the corresponding 
measured and calculated images.  The user may scroll through each field to visualize 
where any significant differences occur.  The gamma results are also displayed in table 
form on the GUI.  As the user scrolls through each field, the verification result is 
highlighted on the GUI as well.  If 95% of the pixels pass gamma (3%, 3 mm), a large 
―PASS‖ is displayed with a green background.  If the images fail the gamma criteria, a 
large ―FAIL‖ is displayed with a red background.  If the percentage of pixels passing 
gamma is between 90% and 95%, a large ―WARNING‖ is displayed with a yellow 
background, and the user is advised to manually inspect the differences. 
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Figure 32: Sample QA printout that is auto-generated by the clinical DPI comparison GUI.  The calculated and 
measured fields are shown, as well as the corresponding 3 mm / 3% gamma image and a profile comparison image.  
Field information is shown at bottom as well as a signature line for the verification.  
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 The final step of the clinical process is to print the QA report for the treatment 
plan.  As seen in Figure 32, the printout was designed to reflect the same information 
that was produced in the Matrixx QA printout: images of the fields, profiles through the 
fields, the gamma image, and plan information and signature lines.  For each field in the 
plan, a soft-copy QA report is saved to disk (in html format) and a hard-copy is sent to 
the local printer.  When the user is finished with verification for a specific patient, the 
verification results are automatically copied to a research database, allowing for further 
future analysis. 
5.2.2. Research Version 
Beyond the clinical mode, this tool provides an excellent framework for analysis of 
images.  Therefore, a research version of the interface was also designed which 
allowed for more manipulation of images as well as various comparison metrics besides 
the gamma metric.  The research interface is shown in Figure 33.  Similar to the clinical 
interface, the first step is for the user to select the directories for the reference and test 
images.  The user is then required to select the individual images for comparison from 
each directory, as the research version was designed for comparison of single images, 
not groups of images. 
 Prior to comparison, each image may be preprocessed in a number of ways.  If 
image noise is a concern, a boxcar filter of user-chosen size may be applied.  Output 
normalization may be performed between the two images.  The normalization is 
calculated by multiplying the test image by the ratio of the sum of all pixels greater than 
10% maximum intensity in the reference image divided by the same pixels in the test 
image. 
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A sub-pixel fast-Fourier-based rigid registration (Guizar-Sicairos, Thurman et al. 
2008) was also coded into the GUI as an option.  To test the accuracy of the 
registration, a reference field was randomly rotated and translated to form one hundred 
test images, which were then registered back to the reference image.  For every test 
image, the registration was found to be accurate within half of a pixel and half of a 
degree.  Since the registration algorithm did not account for scaling (i.e. differences in 
the zoom between the two images), an optional zoom factor correction was coded into 
the GUI as well.  The zoom factor also incorporated the inverse-square law for adjusting 
the intensity of the image.  The intensity adjustment assumes that differences in the 
zoom factor between two images are due to differences in the location of the imager in 
the z-plane. 
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Figure 33: EPID-based delivery verification GUI for research purposes.  The two imported images are displayed in 
the top panels, and the comparison image is displayed in the bottom right panel.  Comparison metrics available are a 
percent difference image, a gamma image, and a pixel intensity deviation (PID) histogram.  The result of the 
comparison is shown in the lower left corner (in this case, the test image passed the accepted tolerance).  
 
The research version of the verification tool also provides several other 
comparison metrics in addition to the gamma metric, which allows for more 
comprehensive analysis of image deviations: 
 A simple percent difference image can be calculated and displayed.  The 
pixel-by-pixel histogram of the percent difference image, termed the pixel 
intensity distribution (PID), can also be displayed.  The PID comparison 
metric was published in Medical Physics (Gordon, Gardner et al. 2012). 
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 If the user desires to analyze a series of images, and not just one single 
image against another, there is capability to calculate a series sigma image.  
In this calculation, the GUI finds all images located in the selected directory, 
and, for each pixel of the images, calculates the standard deviation of the 
pixel intensity over all of the images.  This analysis is useful to reveal 
problematic areas of delivery in a field, whether caused by machine-related 
sources of deviation (e.g. jaw location uncertainty) or patient-related sources 
of uncertainty (e.g. presence of air pockets in the rectum). 
 If two MC images are being compared, and the corresponding uncertainty 
images exist, then a ―Kawrakow-Fippel‖ (KF) comparison may be performed 
(Kawrakow and Fippel 2000).  This analysis reveals areas that differ 
significantly between the two images with respect to their corresponding pixel 
uncertainties.  The user may display the KF image or the histogram of KF 
pixel values. 
All analysis results can be saved to disk as image files or pdf files. 
5.3. Future Improvements 
Implementation of the verification tool into our clinic will start with several test QA cases, 
where past patient treatment information will be used both to calculate and measure 
portal images for several patients.  The appropriate staff will then be trained in how to 
use the GUI to import these images and then perform verification. 
The next step in automation of the verification process is to implement automatic 
generation of calculated images into the treatment planning process, as well as 
automatic placement of the calculated and measured images.  The tool will be further 
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developed so that it will regularly automatically search for new calculated and measured 
images in the appropriate directories.  When matching images are detected, it will 
perform the comparison automatically in the background.  This process allows for a 
more efficient final manual review for each patient QA.  The user can view several 
patient comparison results consecutively, instead of waiting for the comparison 
calculations to be performed between viewing of each set of patient fields. 
During-treatment QA in the verification process is also desired.  The goal of 
during-treatment verification is to avoid gross errors in treatment delivery.  Instead of 
waiting to perform verification until after the treatment fraction is complete, during-
treatment cine images will automatically be imported into the GUI, and compared to the 
predicted images, all while the patient is being treated.  These comparisons will 
inherently incorporate errors due to assumptions made about the unknown patient 
geometry, however, gross deviations (e.g. wrong field, jaw settings, MU, etc…) between 
the measured and calculated images will still be detectable, and the delivery may be 
stopped mid-treatment. 
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6. Conclusion 
The EPID is a useful tool for treatment QA due to its dosimetric stability and convenient 
positioning on the linac gantry arm.  The aim of this work was to improve upon EPID-
based dose verification for ART. 
 Software was developed which improved our institution‘s ability to simulate 
expected DPIs.  The ability to separate the primary and scatter portions of DPIs was 
implemented.  Also, exit fluences can now be outputted as well as DPIs.  A basic 
backprojection component was added to our MC system, allowing for backprojection-
based dose reconstruction in instances where it is deemed appropriate. 
The basic assumption of backprojection-based dose reconstruction, that variation 
in exit fluence is caused by machine-related variability, was tested and found to be 
erroneous.  Interfractional changes in the patient anatomy caused significantly larger 
deviations in exit fluence than the inherent variation in the machine-delivered fluence.  
Exit fluence deviations must not simply be attributed to entrance fluence deviations, 
allowing for a potentially faulty patient dose reconstruction for delivery verification.  
Without knowledge of the during-treatment patient anatomy, dose reconstruction could 
potentially result in a worse estimate of the delivered dose than the planned dose itself.  
Therefore caution is recommended whenever dose reconstruction is desired. 
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Correlation between DPI deviations and DVH deviations was observed, and false 
positives and negatives were examined.  Although positive correlation was found, 
further work must be performed to achieve a higher accuracy in using DPI deviations as 
a predictor for DVH deviations.  A decision tree was proposed detailing when DPI-based 
delivery verification must be sufficient, and when dose reconstruction-based delivery 
verification is permissible.  Potential DPI deviation tolerances were examined which 
predict when there are significant differences between the planned and delivered dose.  
Also, failure to meet tolerance could dictate that the patient anatomy should be re-
imaged. 
A semi-automated dose verification tool was developed for implementation at this 
institution, both for clinical and research purposes.  The clinical tool allows for 
comparison of pretreatment or during treatment DPIs, and provides a measurement of 
treatment delivery success.  The research tool includes several other means of 
comparison of two or more DPIs, and allows the user to manipulate the images 
throughout the comparison.  Currently, the tool will determine if any egregious delivery 
errors have occurred, and report to the user whether the delivery passed within 
tolerance.  The framework for implementation of an EPID-based dose verification 
system at this institution was completed, which will result in both a more efficient and 
more accurate verification process than the current system. 
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9. Appendix II 
 
 
 
Figure 34: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 1.  The planned doses are shown 
as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and 
reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 6 MV. 
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Figure 35: GTV DVHs for patient poses [01, 02 …] for patient 1.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 6 MV. 
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Figure 36: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 1.  
The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the mean 
differences.  For the D95 values, the average delivered dose is 75 cGy greater than the average reconstructed dose.  
Beam energy for this patient was 6 MV. 
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Figure 37: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 2.  The planned doses are shown 
as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and 
reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 6 MV. 
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Figure 38: GTV DVHs for patient poses [01, 02 …] for patient 2.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 6 MV. 
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Figure 39: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 2.  
The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the mean 
differences.  For the D95 values, the average delivered dose is 177 cGy greater than the average reconstructed dose.  
Beam energy for this patient was 6 MV. 
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Figure 40: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 3.  The planned doses are shown 
as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and 
reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 6 MV. 
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Figure 41: GTV DVHs for patient poses [01, 02 …] for patient 3.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 6 MV. 
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Figure 42: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 3.  
The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the mean 
differences.  For the D95 values, the average delivered dose is 18 cGy greater than the average reconstructed dose.  
Beam energy for this patient was 6 MV. 
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Figure 43: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 4.  The planned doses are shown 
as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and 
reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 18 MV.  
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Figure 44: GTV DVHs for patient poses [01, 02 …] for patient 4.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 18 MV. 
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Figure 45: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 4.  
The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the mean 
differences.  For the D95 values, the average delivered dose is 302 cGy greater than the average reconstructed dose.  
Beam energy for this patient was 18 MV. 
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Figure 46: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 5.  The planned doses are shown 
as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and 
reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 6 MV.  
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Figure 47: GTV DVHs for patient poses [01, 02 …] for patient 5.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 6 MV. 
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Figure 48: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 5.  
The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the mean 
differences.  For the D95 values, the average delivered dose is 239 cGy greater than the average reconstructed dose.  
Beam energy for this patient was 6 MV. 
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Figure 49: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 6.  The planned doses are shown 
as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and 
reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 6 MV.  
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Figure 50: GTV DVHs for patient poses [01, 02 …] for patient 6.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 6 MV. 
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Figure 51: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 6.  
The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the mean 
differences.  For the D95 values, the average delivered dose is 128 cGy greater than the average reconstructed dose.  
Beam energy for this patient was 6 MV. 
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Figure 52: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 7.  The planned doses are shown 
as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and 
reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 18 MV.  
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Figure 53: GTV DVHs for patient poses [01, 02 …] for patient 7.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 18 MV. 
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Figure 54: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 7.  
The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the mean 
differences.  For the D95 values, the average delivered dose is 36 cGy greater than the average reconstructed dose.  
Beam energy for this patient was 18 MV. 
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Figure 55: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 8.  The planned doses are shown 
as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and 
reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 6 MV.  
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Figure 56: GTV DVHs for patient poses [01, 02 …] for patient 8.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 6 MV. 
 131 
 
Figure 57: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 8.  
The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the mean 
differences.  For the D95 values, the average delivered dose is 71 cGy greater than the average reconstructed dose.  
Beam energy for this patient was 6 MV. 
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Figure 58: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 9.  The planned doses are shown 
as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and 
reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 6 MV.  
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Figure 59: GTV DVHs for patient poses [01, 02 …] for patient 9.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 6 MV. 
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Figure 60: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 9.  
The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the mean 
differences.  For the D95 values, the average delivered dose is 23 cGy greater than the average reconstructed dose.  
Beam energy for this patient was 6 MV. 
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Figure 61: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 11.  The planned doses are 
shown as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid 
lines) and reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 18 MV.  
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Figure 62: GTV DVHs for patient poses [01, 02 …] for patient 11.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 18 MV. 
 137 
 
Figure 63: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 
11.  The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the 
mean differences.  For the D95 values, the average delivered dose is 57 cGy less than the average reconstructed 
dose.  Beam energy for this patient was 18 MV. 
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Figure 64: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 12.  The planned doses are 
shown as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid 
lines) and reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 18 MV.  
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Figure 65: GTV DVHs for patient poses [01, 02 …] for patient 12.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 18 MV. 
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Figure 66: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 
12.  The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the 
mean differences.  For the D95 values, the average delivered dose is 70 cGy less than the average reconstructed 
dose.  Beam energy for this patient was 18 MV. 
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Figure 67: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 13.  The planned doses are 
shown as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid 
lines) and reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 18 MV.  
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Figure 68: GTV DVHs for patient poses [01, 02 …] for patient 13.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 18 MV. 
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Figure 69: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 
13.  The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the 
mean differences.  For the D95 values, the average delivered dose is 137 cGy greater than the average reconstructed 
dose.  Beam energy for this patient was 18 MV. 
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Figure 70: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 14.  The planned doses are 
shown as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid 
lines) and reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 18 MV.  
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Figure 71: GTV DVHs for patient poses [01, 02 …] for patient 14.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 18 MV. 
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Figure 72: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 
14.  The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the 
mean differences.  For the D95 values, the average delivered dose is 127 cGy greater than the average reconstructed 
dose.  Beam energy for this patient was 18 MV. 
 147 
 
Figure 73: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 16.  The planned doses are 
shown as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid 
lines) and reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 6 MV.  
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Figure 74: GTV DVHs for patient poses [01, 02 …] for patient 16.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 6 MV. 
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Figure 75: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 
16.  The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the 
mean differences.  For the D95 values, the average delivered dose is 5 cGy greater than the average reconstructed 
dose.  Beam energy for this patient was 6 MV. 
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Figure 76: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 18.  The planned doses are 
shown as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid 
lines) and reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 6 MV.  
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Figure 77: GTV DVHs for patient poses [01, 02 …] for patient 18.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 6 MV. 
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Figure 78: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 
18.  The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the 
mean differences.  For the D95 values, the average delivered dose is 60 cGy greater than the average reconstructed 
dose.  Beam energy for this patient was 6 MV. 
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Figure 79: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 19.  The planned doses are 
shown as the bolded black solid lines.  For each simulated treatment fraction, both the delivered doses (thin solid 
lines) and reconstructed doses (dashed lines) are shown.  Beam energy for this patient was 18 MV.  
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Figure 80: GTV DVHs for patient poses [01, 02 …] for patient 19.  The planned dose is shown as the bolded black 
solid line.  For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses 
(dashed lines) are shown.  Beam energy for this patient was 18 MV. 
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Figure 81: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 
19.  The x-axes represent the dose difference in units of cGy.  The numbers in the red/green boxes represent the 
mean differences.  For the D95 values, the average delivered dose is 3 cGy greater than the average reconstructed 
dose.  Beam energy for this patient was 18 MV. 
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Figure 82: Distribution of bladder D25 deviations for each patient.  Delivered versus planned deviations are shown by 
the blue triangles.  Backprojected versus planned deviations are shown by the purple x‘s.  The mean deviations 
between backprojected and delivered dose are shown by the orange circles. 
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Figure 83: Distribution of bladder D50 deviations for each patient.  Delivered versus planned deviations are shown by 
the blue triangles.  Backprojected versus planned deviations are shown by the purple x‘s.  The mean deviations 
between backprojected and delivered dose are shown by the orange circles. 
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Figure 84: Distribution of rectum D17 deviations for each patient.  Delivered versus planned deviations are shown by 
the blue triangles.  Backprojected versus planned deviations are shown by the purple x‘s.  The mean deviations 
between backprojected and delivered dose are shown by the orange circles. 
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Figure 85: Distribution of rectum D35 deviations for each patient.  Delivered versus planned deviations are shown by 
the blue triangles.  Backprojected versus planned deviations are shown by the purple x‘s.  The mean deviations 
between backprojected and delivered dose are shown by the orange circles. 
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